Information Products on Pharmaceuticals - Renouf Publishing Co. Ltd.

oms-catalogue 15/07/03 11:32 Page 1 

Catal ogue 

<strong>Information</strong> <strong>Products</strong> 

on Pharmaceuticals 

2003 

World Health Organization


INFORMATION 

WORLD HEALTH ORGANIZATION – MARKETING AND DISSEMINATION 

<strong>Information</strong> <strong>Products</strong> on Pharmaceuticals 2003 

This information products catalogue on pharmaceuticals provides bibliographic and descriptive 

information on over 93 recent WHO publications and CD-ROMs relevant to the selection, use, 

quality control and quality assurance, safety assessment, regulation, and correct prescribing 

of medicines. <strong>Information</strong> products are an outgrowth of WHO efforts to unite governments, 

prescribers, dispensers, consumers, and the pharmaceutical industry in a search for ways to 

assure that safe, effective, and affordable medicines are universally available – and widely used. 

Most of this information stems from long-standing WHO programmes responsible for the 

international standardization of biological substances, the assignment of generic names, the 

development of standards in quality assurance and of quality specifications, the designation 

of essential medicines, and the assessment of the abuse potential of psychotropic drugs. 

Other information products provide current scientific information in the form of fact sheets, 

newsletters, teaching and training documents. <strong>Information</strong> products free of charge are listed 

in each section and relevant URL addresses are given for information available in electronic form. 

Whatever their individual topic or focus, all information products participate in the larger 

WHO objective of realizing the advantages promised by modern medicines in ways that make 

a difference in human health on the largest possible scale. 

How to order 

An order form is contained in this catalogue on page 43. You can also order online at the 

following address : http://bookorders.who.int 

WHO information products can be ordered from sales agents (see list at the end of the 

catalogue) or directly from WHO. Orders addressed to WHO must be accompanied by payment 

in Swiss francs, EURO or US dollars. Payment by credit card is accepted (see order form). 

Bank address: UBS SA, Agence de l’OMS, CH-1211 Geneva 27, Switzerland 

– Swift Code UBSW CH ZH 12 A 

– Swiss franc account no. 279-D3-100-897.0 

– US dollar account no. 240-CO-169-920.3 

– Euro account no. 240-CO-169-920.1 

Email address for direct orders: bookorders@who.int 

An alphabetical index of titles is provided at the end. 

In developing countries 

Developing countries benefit from at least a 30% discount on the regular price indicated 

in this catalogue for the books published by WHO. 

Language editions 

The following abbreviations are used in bibliographic entries to indicate the availability of 

language editions: Ar = Arabic; C = Chinese; E = English; F = French; G = German; R = Russian; 

S = Spanish; E/F = Bilingual edition English/French. An asterisk (*) indicates a language edition 

in preparation. 

Catalogue online 

This catalogue can also be consulted on our website at the following address: 

http://bookorders.who.int/catalogues. For additional information on our information 

products, please visit our website: http://bookorders.who.int 

Tel.: +41 22 791 24 76 Fax: +41 22 791 48 57 

Email: publications@who.int 

Order online: http://bookorders.who.int 

WHO Website: www.who.int 

World Health Organization 

Marketing and Dissemination 

CH-1211 Geneva 27 

Switzerland 

MDI.PHA.203


CONTENTS 

Selection and Use 

Drug Policy 

Economics and Financing 

Supply and Procurement 

Quality Assurance and Safety 

The International Pharmacopoeia 

Drug Prescribing 

Legislation and Regulation 

Publications from the South Centre 

Ethics and Safety Guidelines 

WHO Collaborating Centre 

for International Drug Monitoring 

Medicinal Plants 

Traditional Medicine 

Psychotropic Drugs 

Periodicals and Subscriptions 

Useful Web addresses 

Title index 

Addresses 

Order form 

Sales agents 

2 

5 

6 

7 

8 

17 

21 

25 

27 

28 

30 

31 

35 

36 

37 

38 

39 

41 

43 

45 

1


SELECTION AND USE 

WHO Model Formulary 2002 

Available now 

on CD-ROM 

The WHO Model Formulary presents formulary information on over 

300 medicines included on the WHO Model List of Essential Drugs, 

as a reference for national and institutional drugs and therapeutic 

committees. It is also a valuable source of independent and unbiased 

information for students and prescribers who are interested 

in focusing their prescribing on those medicines which are globally 

recognized as essential. 

This pocket-sized book contains 27 sections covering anaesthetics, 

analgesics, antiallergics, antidotes, anticonvulsants, anti-infective 

drugs, antimigraine drugs, antineoplastic and immunosuppressives 

drugs and drugs used in palliative care, antiparkinson drugs, drugs 

affecting the blood, blood products and plasma substitutes, cardiovascular 

drugs, dermatological drugs, diagnostics, disinfectants 

and antiseptics, diuretics, gastrointestinal drugs, hormones and 

contraceptives, immunologicals, muscle relaxants and cholinesterase 

inhibitors, ophthalmological preparations, drugs used in obstetrics, 

peritoneal dialysis solution, psychotherapeutic drugs, drugs acting on 

the respiratory tract, solutions correcting water, electrolyte and 

acid-base disturbances, vitamins and minerals. The four successive 

annexes include information on drug interactions, pregnancy, 

breast-feeding, renal and liver impairments. 

Table of Contents 

2 

Section 1: Drugs used in Anaesthesia 

Section 2: Analgesics, antipyretics, 

nonsteroidal anti-inflammatory 

drugs, drugs used to treat gout 

and disease-modifying 

antirheumatic drugs 

Section 3: Antiallergics and drugs used in 

anaphylaxis 

Section 4: Antidotes and other substances 

used in poisonings 

Section 5: Anticonvulsants/antiepileptics 

Section 6: Anti-infective drugs 

Section 7: Antimigraine drugs 

Section 8: Antineoplastic and 

immunosuppressive drugs 

and drugs used in palliative care 

Section 9: Antiparkinson drugs 

Section 10: Drugs affecting the blood 

Section 11: Blood products and plasma 

substitutes 

Section 12: Cardiovascular drugs 

Section 13: Dermatological Drugs (topical) 

Section 14: Diagnostics 

Section 15: Disinfectants and Antiseptics 

Section 16: Diuretics 

Section 17: Gastrointestinal drugs 

Section 18: Hormones and other endocrine 

drugs and contraceptives 

Section 19: Immunologicals 

Section 20: Muscle relaxants (peripherally 

acting) and cholinesterase inhibitors 

Section 21: Ophthalmological preparations 

Section 22: Drugs used in Obstetrics 

Section 23: Peritoneal dialysis solution 

Section 24: Psychotherapeutic drugs 

Section 25: Drugs acting on the Respiratory 

tract 

Section 26: Solutions correcting water, 

electrolyte and acid-base 

disturbances 

Section 27: Vitamins and minerals 

Appendix I: Interactions 

Appendix II: Pregnancy 

Appendix III: Breast Feeding 

Appendix IV: Renal Impairment 

Appendix V: Liver impairment 

2002 , 500 pages [E] 

ISBN 92 4 154559 3 

Sw.fr. 40.–/US $36.00 

In developing countries: Sw.fr. 20.– 

Order no.1150499 

CD-ROM, 2003 [E] 

ISBN 92 4 154600 X 

Sw.fr. 40.–/US $36.00 


Order no. 1990019


WHO Medicines Bookshelf 

CD-ROM 

The Selection and Use 

of Essential Medicines 

Report of the WHO Expert 

Committee (including the 12th 

Model List of Essential 

Medicines) 

Handbook on Access 

to HIV/AIDS-Related 

Treatment: A Collection 

of <strong>Information</strong>, Tools and 

Resources for NGOs, CBOs 

and PLHA Groups 

The WHO Medicines Bookshelf 

CD-ROM contains a selection of 

over 250 publications (more than 

16 000 pages) in English, French 

and Spanish dealing with essential 

medicines. The publications included 

cover the whole field of interest 

of WHO's Department of Essential 

Drugs and Medicines Policy (EDM), 

including access to essential medicines, 

rational use of drugs, national 

drug policy, quality and safety of 

medicines and traditional medicine. 

The CD-ROM also contains a mirror 

of the EDM web site (totalling 315 

MB) that can be accessed by clicking 

the 'EDM mirror' button from 

the entry screen. This provides the 

opportunity for users in developing 

countries, who lack a fast Internet 

connection, to browse the site at 

their own leisure. 

This report presents the recommendations 

of the WHO Expert 

Committee responsible for 

updating the WHO Model List of 

Essential Medicines. The first part 

contains an update on the revised 

procedures for updating the Model 

List and the development of the 

WHO Essential Medicines Library. 

It continues to present a summary 

of the Committee’s considerations 

and justifications for additions and 

changes to the 12th Model List, 

including its recommendation to 

add ten antiretroviral medicines. 

The annexes include the 12th WHO 

Model List of Essential Medicines 

in its usual presentation and, for 

the first time, in the five-level 

Anatomical Therapeutic Chemical 

(ATC) classification system. 

This handbook is intended to assist 

nongovernmental organizations, 

community-based organizations 

and groups of people living with 

HIV/AIDS in finding ways of understanding, 

planning and undertaking 

work on HIV/AIDS-related treatment. 

It builds on practical skills by using 

participatory activities and sharing 

experiences; provides a training 

resource for NGO support prgrammes, 

training organizations and individuals; 

and facilitates ongoing learning about 

the treatment work being carried out 

by the various groups involved. 

Applicable at all levels of experience, 

the handbook offers flexibility to 

facilitators who need to gear their 

work towards specific schedules 

or situations. 

3 

2002 , CD-ROM [E] 

ISBN 92 4 159025 4 

Swiss francs 20.–/US $18.00 



Technical Report Series, No. 914 

2002 , vi + 122 pages [E] 

ISBN 92 4 120914 3 


In developing countries: Sw.fr. 16.10 


Joint United Nations Programme 

on HIV/AIDS 

2003, 130 pages [E] 

ISBN 92 9173 161 7 



Order no. 1880013


SELECTION AND USE 

Essential Drugs for Primary 

Health Care 

A Manual for Health Workers 

Third edition 

The New Emergency Health 

Kit 1998 

Lists of Drugs and Medical 

Supplies for 10,000 People for 

Approximately Three Months 

Second edition 

4 

An illustrated manual designed to help community 

health workers learn how to use simple drugs to treat 

common illnesses. Specific to health conditions in 

South-East Asian countries, the book uses simple 

explanatory texts and illustrations to communicate 

instructions for treating illnesses and knowing when 

a patient must be referred to a doctor. 

Explains how to use standardized packages of 

essential drugs, supplies, and equipment to provide 

effective medical care under the primitive, demanding 

conditions that follow emergencies or disasters. Both 

the concept and the contents of the kit, which was 

developed by WHO in collaboration with a large 

number of international and non-governmental 

agencies, are designed to expedite the provision of 

supplies in line with priority health needs. Although 

primarily addressed to relief agencies, the book also 

provides useful information for national authorities 

and hospital managers interested in stockpiling drugs 

and supplies in advance. 

Now in its second edition, the book has been significantly 

revised to reflect changes in the selection of 

drugs included in the WHO Model List of Essential 

Drugs and to bring recommendations in line with 

a new United Nations list of priority drugs for use 

in acute emergencies. New in this edition are WHO 

guidelines for drug donations and model guidelines 

for the international provision of controlled medicines 

for emergency care. 

WHO Regional Office for South-East Asia 

SEARO Regional Health Papers, No. 16 

2000, v + 128 pages [E] 

ISBN 92 9022 185 2 



Order no. 1583016 

1998, vi + 73 pages [E, F] 

WHO/DAP/98.10 



Order no. 1931018


DRUG POLICY 

Free of charge 

For information on availability 

of these documents, 

please refer to: 

www.who.int/medicines 

How to Develop and 

Implement a National 

Drug Policy 

Second Edition 

Indicators for Monitoring 

National Drug Policies 

A Practical Manual 


WHO Medicines Strategy 

Framework for Action in 

Essential Drugs and Medicines 

Policy 2000–2003 

This strategy evolved from the 

revised drug strategy originally 

adopted by the World Health 

Assembly as long ago as 1986. 

It incorporates four main objectives: 

to frame and implement national 

drug policy, to ensure access to 

essential drugs, to ensure quality, 

safety and efficacy of all medicines, 

and to promote rational drug use. 

2000, viii + 70 pages [E, F] 

WHO/EDM/2000.1 

Electronic access: 

http://www.who.int/medicines/ 

strategy/stmission.shtml#st 

In this new edition guidelines are 

given on developing a national 

drug policy - a crucial ingredient 

in every country's national health 

strategy and an invaluable framework 

to identify national goals and 

commitments. This expanded and 

extensively revised second edition 

discusses key policy components. 

These include the selection of 

essential drugs, affordability, 

finance and supply, regulation 

and quality assurance, rational use, 

research, human resources, monitoring 

and evaluation. 

Each chapter presents useful 

advice and references to other 

sources of more detailed technical 

information. A valuable resource 

for health professionals, policymakers 

and researchers, the publication 

takes readers through the 

process of planning, developing, 

implementing and monitoring a 

comprehensive policy framework 

based on a country's unique needs, 

priorities and resources. 

Presents and explains a simple yet 

powerful new methodology for 

gathering the data needed to 

improve national drug policies. 

Both the public and private sectors 

are addressed. The methodology, 

which was finalized after extensive 

expert consultations and testing in 

different settings, provides a logical 

and systematic tool for identifying 

problems in meeting the main 

objective of a national drug policy: 

to assure that effective and 

affordable essential drugs are 

widely available, of good quality, 

and wisely used. 

WHO Policy Perspectives 

on Medicines 

No 1. WHO Medicines Strategy 

2000-2003 

No 2. Traditional Medicine: 

Growing Needs and 

Potential 

No 3. Globalization, TRIPS and 

access to pharmaceuticals 

No 4. The Selection of Essential 

Medicines 

No 5. Promoting rational use 

of medicines: core 

components 

No 6. How to develop and 

implement a national 

drug policy 



organization/ood/ood6pagers.shtml 

5 

2002, 91 pages [E, F, S] 

ISBN 92 4 154547 X 

Swiss francs 26.-/US $23.40 


Order no. 1152287 

by P. Brudon-Jakobowicz, 

J.-D.Rainhorn and M.R. Reich 

2000, x + 216 pages [E, F, S*] 

WHO/EDM/PAR/99.3 



Order no. 1932066


ECONOMICS AND FINANCING 


For information on availability of these documents, 

please refer to: www.who.int/medicines 

6 

Guide to Drug Financing 

Mechanisms 

A practical guide to the use 

of economic criteria to analyse a 

country’s pharmaceutical sector and 

identify ways to improve the drug 

supply. Addressed to decisionmakers 

responsible for formulating 

drug policies, the book aims to 

facilitate the analysis of expenditure 

on drugs within the context of 

a government’s overall economic 

policies and priorities. With this 

goal in mind, the book explains the 

many complex economic factors 

that influence the drug supply and 

identifies the corresponding policy 

options available for introducing 

changes in different situations. 

by J. Dumoulin, M. Kaddar, and 

G.Velásquez 

1998, vii + 55 pages [E, F] 

ISBN 92 9036 068 2 



Order no. 1150461 

Cost-containment Mechanisms 

for Essential Medicines, 

including Antiretrovirals, 

in China 

Health Economics and Drugs EDM Series, 

No. 13 

2002,27 pages [E] 


Electronic access: http://www.who.int/ 

medicines/library/par/who-edm-par-2003- 

6/CostContainmentEnglish.pdf 

Implications of the DOHA 

Declaration on the TRIPS 

Agreement and Public Health 

This document considers the 

implications of the Doha Declaration, 

and includes discussions on compulsory 

licensing and transfer of technology 

to countries with little or no manufacturing 

capacity or insufficient market 

demand. 

Health Economics and Drugs Series, No. 12 

2002, 68 pages [E, F, S*] 



medicines/library/par/who-edm-par-2002- 

3/doha-implications.doc 

Network for Monitoring the 

Impact of Globalization and 

TRIPS on Access to Medicines 

The last decade has witnessed a sharp 

acceleration in the processes of 

economic globalization and a major 

increase in the number, and expansion 

of the scope, of international trade 

agreements. This is a report of a 

meeting held in 2001 at which WHO 

initiated a process to monitor and 

analyze the impact of trade agreements 

on access to drugs in partnership 

with four WHO collaborating 

centres in Brazil, Spain, Thailand 

and the United Kingdom. 


2002, 67 pages [E] 



medicines/library/par/who-edm-par-2002 

1/networktrips.pdf 

Public-Private Roles 

in the Pharmaceutical Sector 

Implications for Equitable Access 

and Rational Drug Use 

Aimed at policy makers at country, 

regional and international levels, this 

document provides a practical guide 

to how changing public-private roles in 

the pharmaceutical sector may affect 

drug accessibility and rational use. 


1997, 102 pages [E, F, S] 

WHO/DAP/97.12 

Electronic access: http://www.who.int/me 

icines/library/dap/who-dap-97-12/who-dap 

97-12.htm 

Globalization and Access 

to Drugs 

Perspectives on the WTO/TRIPS 

Agreement. 

The impact of globalization on access 

to drugs is of increasing interest, and 

this document informs people in the 

health sector with no legal background 

about this complex issue. 


1998, 98 pages [E, F, S, C, Ar] 

WHO/DAP/98.9 Revised 


medicines/library/dap/who-dap-98-9- 

rev/who-dap-98-9.htm 

Health Reform and Drug 

Financing 

Selected Topics 

This document discusses reform primarily 

from the perspective of certain 

financial aspects of health-public 

financing, health insurance, user 

charges, donor financing and drug 

donations, and development loans. 


1998, 44 pages [E, F, S] 

WHO/DAP/98.3 


medicines/library/dap/who-dap-98-3/ 

who-dap-98-3.htm


SUPPLY AND PROCUREMENT 






Practical Guidelines 

on Pharmaceutical 

Procurement for Countries 

with Small Procurement 

Agencies 

This publication is aimed at 

countries with small procurement 

agencies and provides practical and 

simple guidelines for the purchase 

of pharmaceutical products. Various 

types of tender mechanisms are 

described, as is direct procurement. 

Emphasis is given to the importance 

of pre-qualifying suppliers to ensure 

purchase of good quality products. 

This book does not cover all aspects 

of the drug management cycle, but 

it does describe the core principles 

of procurement and various 

methods of tendering for drug 

procurement. It discusses the 

advantages and disadvantages of 

these methods as well as the tender 

process itself. Model questionnaires 

for prequalification of suppliers, 

model tender invitations and an 

inspection checklist for drug receipts 

that can be modified and extended 

to meet local requirements are 

enclosed. 

Guidelines for Safe 

Disposal of Unwanted 

Pharmaceuticals in and 

after Emergencies 

Interagency Guidelines 

How can unwanted and unusable 

pharmaceuticals be disposed of 

safely? These guidelines – which 

are the result of collaboration 

between 13 international and nongovernmental 

agencies – provide 

advice on the safe disposal of 

unusable pharmaceuticals in 

emergencies and in countries 

where official assistance and advice 

may not be available. 


http://www.who.int/ 

medicines/library/par/who-edmpar-99-2/who-edm-par-99-2.htm 

Operational Principles for 

Good Pharmaceutical 

Procurement 

Interagency guidelines 

Pharmaceutical procurement is a 

complex process and problems are 

common. This document from the 

Interagency Pharmaceutical 

Procurement Group sets out four 

strategic objectives and 12 operational 

principles for good procurement, 

which can be adapted by 

users. 

2000, 24 pages [E, F, S] 



http://www.who.int/medicines/library/ 

par/who-edm-par-99-5/who-edm-par- 

99-5.htm 

Guidelines for Drug 

Donations 

Revised 1999. Second Edition. 

Interagency Guidelines 

There are many types of drug 

donation: rapid response to an 

emergency, the philanthropic aims 

of organizations, and those 

targeted for use by individual 

health facilities. By describing 

‘good donation practice’, these 

guidelines aim to improve the 

quality of drug donations. 

1999, 19 pages [E, F, S] 




par/who-edm-par-99-4/who-edm-par-99- 

4.htm 

7 

WHO Regional Office 

for the Western Pacific 

2002, 56 pages [E] 

ISBN 92 9061 014 X 

Swiss francs 10.–/US$9.00 


Order no. 1520010 

1999, 31 pages [E, F, S] 




Order no. 1930154


QUALITY ASSURANCE AND SAFETY 

International 

Nonproprietary Names (INN) 

for Pharmaceutical Substances 

List 1-45 of Proposed INNs 

and List 1-85 of 

Recommended INNs 

Cumulative List No.10 

CD-ROM 

International 

Nonproprietary Names (INN) 

for Pharmaceutical 

Substances 

List 1-45 of Proposed INNs 

and List 1-85 of Recommended INNs 

Cumulative List No.10 

8 

The aim of the INN System has been to provide health professionals 

with a unique and universally available designated name to identify 

each pharmaceutical substance. The existence of an international 

nomenclature for pharmaceutical substances, in the form of INNs, 

is important for the clear identification, safe prescription and dispensing 

of medicines to patients, and for communication and exchange of 

information among health professionals and scientists worldwide. 

This tenth Cumulative List CD-ROM is intended as a reference source 

for national drug regulatory authorities, the pharmaceutical industry 

and health professionals. It supersedes the ninth list published in 1996. 

It contains over 7250 INNs for individual pharmaceutical substances, 

including about 740 new names proposed since the previous Cumulative 

List was prepared. It is produced in a multilingual format: English and 

French introductory texts, together with a listing of INNs in Latin, English, 

French, Russian and Spanish. 

<strong>Information</strong> on Proposed and Recommended International 

Nonproprietary Names (INNs) can also be consulted on the following 

website: 

http://mednet.who.int 

Special pricing scheme 

for multiple users: 

2-10 users: Swiss francs 350.–/US $315.00 

In developing countries: Swiss francs 175.–, order no. 0991010 

11-99 users: Swiss francs 450.–/US $405.00 


100 or more users: Swiss francs 600.–/US $540.00 


2002, CD-ROM [E/F] 

ISBN 92 4 056019 X 

Swiss francs 290.–/US $261.00 for individual user 

In developing countries: Sw. fr. 100.– 

Order no. 0990010


Basic Tests for Drugs 

Pharmaceutical Substances, 

Medicinal Plant Materials 

and Dosage Forms 

Basic Tests 


Dosage Forms 

Basic Tests 


Substances 

Describes tests for 23 pharmaceutical 

substances and 58 pharmaceutical 

dosage forms, most of which are 

included in the WHO Model List 

of Essential Drugs. Basic tests for 

confirming the identity of four 

commonly used medicinal plant 

materials are also included. 

Sets out rapid screening tests 

required to verify the identity of 

some 150 pharmaceutical dosage 

forms in common use. The tests, 

which are simple and readily applicable, 

make it possible to confirm 

the identity of pharmaceutical substances 

in tablet, capsule, solution, 

lotion and other forms in those 

cases where quality is in doubt. 

The basic tests may also be applied 

to determine whether gross degradation 

has occurred despite high 

standards of packaging. 

"... describes simple tests of powerful 

use in the primary detection 

of degradation, tampering, 

adulteration, and counterfeiting ... 

admirably serves its purpose..." 

– Journal of the Royal Society of 

Health 

Presents simplified tests for verifying 

the identify of pharmaceutical 

substances and detecting gross 

degradation. The 321 substances 

covered represent the majority of 

drug substances contained in the 

WHO Model List of Essential Drugs 

as well as a number of other widely 

used drug substances. For each, 

tests have been devised to serve as 

a simple and readily applicable 

method of verification of identity 

when a fully equipped laboratory 

is not available. 

"... will serve as a useful component 

of the WHO programme 

for quality assurance in the 

pharmaceutical supply system..." 

– Indian Journal of Hospital Pharmacy 

9 

1998, iii + 91 pages [E, F, S, R, C] 

ISBN 92 4 154513 5 



Order no. 1150462 

1991, v + 129 pages [C, E, F, S] 

ISBN 92 4 154418 X 



Order no. 1150359 

1986, 210 pages [Ar, C, E, F, S] 

ISBN 92 4 154204 7 



Order no. 1150245



Quality Assurance of 

Pharmaceuticals 

A Compendium of Guidelines 

and Related Materials 

Volume 1 

Quality Assurance of 

Pharmaceuticals 

A Compendium of Guidelines 

and Related Materials 

Volume 2: Good Manufacturing 

Practices and Inspection 

Quality Control Methods 

for Medicinal Plant 

Materials 

10 

Draws together twenty-two WHO 

guidelines relevant to the quality 

assurance and control of pharmaceutical 

products. Most of these 

guidelines have appeared as annexes 

in various reports of the WHO 

Expert Committee on Specifications 

for Pharmaceutical Preparations. 

Others are published here for the 

first time. By making these available 

in a single reference work, the 

book facilitates access to the complete 

body of WHO guidelines and 

recommendations issued to assist 

national drug regulatory and 

control authorities, particularly in 

developing countries. When 

viewed together, the collected 

guidelines also underscore the 

need for a comprehensive system 

of quality assurance and illustrate 

its various technical and administrative 

components in a logical way. 

Draws together twelve WHO 

guidelines related to good manufacturing 

practives (GMP) and to 

the inspection of pharmaceutical 

manufacturers and distribution 

channels. Most of these guidelines 

have appeared as annexes in 

various reports of the WHO Expert 

Commitee on Specifications for 

Pharmaceutical Preparations. By 

making these available in a single 

reference work, the book facilitates 

access to the complete body of 

WHO guidelines and recommendations 

aimed at ensuring the 

pharmaceutical products are 

manufactured in compliance with 

internationally accepted standards 

for quality and safety. 

A collection of recommended test procedures 

for assessing the identity, purity, 

and content of medicinal plant 

materials. Intended to assist national 

laboratories engaged in drug quality 

control, the manual responds to the 

growing use of medicinal plants, the 

special quality problems they pose, and 

the corresponding need for international 

guidance on reliable methods 

for quality control. Recommended 

procedures – whether involving visual 

inspection or the use of thin-layer 

chromatography for the qualitative 

determination of impurities – should 

also prove useful to the pharmaceutical 

industry and pharmacists working with 

these materials. 

1997, vi + 238 pages [E, F, R] 

ISBN 92 4 154504 6 



Order no. 1150452 

1999, v + 198 pages [E, F*, R] 

ISBN 92 4 154526 7 



Order no. 1152452 

1998, viii + 115 pages [E] 

ISBN 92 4 154510 0 



Order no. 1150451


WHO Expert Committee on Specifications 

for Pharmaceutical Preparations 

Thirty-seventh Report 

WHO Expert Committee on Specifications 

for Pharmaceutical Preparations 

Thirty-sixth Report 

This report presents the recommendations of an 

international group of experts convened by the World 

Health Organization to consider matters concerning 

the quality assurance of pharmaceuticals and 

specifications for drug substances and dosage forms. 

This committee reviews and adopts guidelines that 

have been prepared reflecting consensus obtained 

during a large international consultative process. 

Of particular relevance to drug regulatory authorities 

and pharmaceutical manufacturers, the report 

discusses activities related to the development of 

The International Pharmacopoeia and basic tests for 

pharmaceutical substances and dosage forms, 

as well as quality control of reference materials, good 

manufacturing practices (GMP), stability studies, 

inspection, hazard analysis, procurement, storage and 

other aspects of quality assurance of pharmaceuticals, 

and regulatory issues. 

The report is complemented by a number of annexes, 

including recommendations on the risk of transmitting 

animal spongiform encephalopathy agents via 

medicinal products, guidelines on GMP for pharmaceutical 

products, a model certificate for GMP and 

guidance on a GMP inspection report. The final 

annexes provide guidance on the application of 

Hazard Analysis and Critical Control Point (HACCP) 

method to pharmaceuticals, good storage practices 

and a procedure for assessing acceptability of 

pharmaceutical products for purchase by agencies 

of the United Nations. 


2002 , viii + 136 pages [E] 

ISBN 92 4 120908 9 




Sets out a series of twelve international guidelines and 

other recommendations intended to assist national 

drug regulatory authorities and manufacturers in 

the quality assurance of pharmaceutical products. 

The report also responds to the need to extend previously 

issued WHO guidelines for good manufacturing 

practices (GMP) to cover several special circumstances 

as well as guidance for inspectorates. 

List of adopted guidelines: 

Quality Control Laboratory related: 

• Guideline on "Good Practices for National 

Pharmaceutical Control Laboratories" 

(with Model Test Report and List of equipment 

for pharmaceutical control laboratories appended) 

• Model Certificate of Analysis 

• Considerations for requesting analysis of drug 

samples 

• List of International Chemical Reference Substances 

• List of International Infrared Reference Spectra 

GMP (updates and reviews) 

• GMP in pharmaceutical production 

(essential elements) 

• GMP for sterile pharmaceutical products 

(updated text) 

Inspection related: 

• Guidelines on Pre-approval inspection 

• WHO quality systems requirements for national 

GMP inspectorates 

• Guidance on "comparative products" for 

equivalence assessment of interchangeable 

multisource (generic) products 

• General Aspects of Packaging 

• Guidelines on the use of INN for Pharmaceutical 

Substances 


2002, 215 pages [E, F*, S] 

ISBN 92 4 120902 X 



Order no. 1100902 

11



WHO Expert Committee on 

Biological Standardization 

Fifty-first Report 



Fiftieth Report 



Forty-eighth Report 

12 


of a WHO Expert Committee 

commissioned to coordinate 

activities leading to the adoption of 

international requirements for the 

production and control of vaccines 

and other biologicals and the establishment 

of international biological 

reference materials. The report starts 

with a discussion of general issues 

brought to the Committee’s attention 

and provides information on the 

status and development of reference 

materials for various antibodies, 

antigens, blood products and related 

substances, cytokines, growth factors, 

and endocrinological substances. 

The second part of the report, of 

particular relevance to manufacturers 

and national control authorities, contains 

an addendum to recommendations 

for the production and control 

of oral poliomyelitis vaccine, 

recommendations for production 

and quality control of inactivated 

poliomyelitis vaccine, and guidelines 

for live attenuated Japanese 

encephalitis vaccine. 


of a WHO Expert Committee 

commissioned to coordinate activities 

leading to the adoption of international 

requirements for the production 

and control of vaccines and 

other biologicals and the establishment 

of international biological 

reference materials. 

The report starts with a discussion 

of general issues brought to the 

Committee’s attention and provides 

information on the status and 

development of reference materials 

for various antibodies, antigens, 

blood products and related 

substances, cytokines, growth 

factors, and endocrinological 

substances. 

The second part of the report, of 

particular relevance to manufacturers 

and national control authorities, 

contains recommendations 

for the production and control 

of oral poliomyelitis vaccine, an 

amendment to the requirements for 

meningococcal polysaccharide 

vaccine, and a decision-tree for 

setting priorities in the development 

of reference materials. Also included 

are guidelines for the preparation, 

characterization, and establishment 

of standards and reference reagents 

for biological substances. 

Presents the recommendations of a 

WHO expert committee commissioned 

to coordinate a range of 

research and other activities needed 

to assure the purity, potency, 

safety, and stability of biological 

products used in medicine. Issues 

include progress in the establishment 

of cytokine standards, efforts 

to harmonize technical requirements 

for vaccine production and 

licensing, the implications for 

vaccine requirements of the 

Agreement on Technical Barriers to 

Trade of WTO, and safety questions 

arising from the detection by very 

sensitive polymerase-chain-reaction-based 

methods of low levels 

of reverse transcriptase activity in 

live viral vaccines prepared in 

chicken cells. 

IN PREPARATION 


2002 , vi + 104 pages [E] 

ISBN 92 4 120910 0 


In developing countries: Sw.fr.14.– 



2001 , vi + 108 pages [E] 

ISBN 92 4 120904 6 





1999, vi + 111 pages [E, F, S] 

ISBN 92 4 120889 9 



Order no. 1100889


Guidelines on the Use 

of International 

Nonproprietary Names 

(INNs) for Pharmaceutical 

Substances 

Explains the system of international 

nonproprietary names (INNs) 

administered by WHO to ensure 

that each pharmaceutical substance 

or active pharmaceutical 

ingredient is identified by a unique 

name that is universally recognized 

and universally accessible as public 

property. This system of "generic" 

names was introduced by WHO in 

1950 as a mechanism for ensuring 

the clear identification of medicinal 

drugs, promoting their safe 

prescribing and dispensing, and 

facilitating international scientific 

communications. 

13 

1997, iii + 36 pages [E] 

WHO/PHARM S/NOM 1570 



Order no. 1930120



Guidelines for ATC 

Classification 

and DDD Assignment 

5th Edition 

The Guidelines for ATC classification and DDD assignment 

(version 2002) describes the structure of the 

Anatomical Therapeutic Chemical (ATC) classification 

system and the main principles and procedures for 

assigning ATC codes for medicines. The concept of the 

Defined Daily Dose (DDD) is explained as well as principles 

and procedures for assigning DDDs for medicines. 

Different uses of the ATC/DDD methodology are 

described. The book includes all ATC headings down to 

the ATC 4th level assigned by the WHO Collaborating 

Centre in Oslo. Comments regarding specific ATC and 

DDD assignments are included for most of the ATC 

levels. The comments describe particular issues that 

have been discussed and resolved by consensus of the 

WHO International Working Group for Drug Statistics 

Methodology during deliberation while establishing 

ATC/DDDs. Guidelines on how to assign DDDs for 

combination products are added under the respective 

ATC levels. 

14 

ATC Index with DDDs 

This ATC Index with DDDs (version 2002) includes all 

medicines with a final ATC code and a final DDD 

assigned at the time of issuing. The list includes nonproprietary 

drug names and no brand names. 

The index comprises two lists: 

• List A: This list is sorted according to ATC code, and 

gives the complete ATC classification, i.e. all ATC 

levels. All final DDDs, which are established for 

single substances, are included in this list. DDDs 

for combination products are not included. 

• List B: The alphabetical index, sorted according to 

nonproprietary drug names, should be used to look 

up the ATC code for a substance. This list includes 

ATC 5th levels only. 

The Guidelines for ATC Classification and DDD Assignment and the ATC Index 

with DDDs are updated annually (in January). 

To order, please contact: 

WHO Collaborating Centre for Drug Statistics Methodology 

P.O. Box 183, Kalbakken, N-0903 Oslo, Norway 

Email: whocc@nmd.no 

Tel: +47 22 16 98 11 – Fax +47 22 16 98 18 

Both publications are available in English, Spanish and German versions 

Price for the set: US $90.00 

Separate edition: US $50.00


CD-ROM on WHO Basic Training 

Modules on GMP 

A resource and study pack for trainers 

CD-ROM on WHO Supplementary Training 

Modules on GMP: Validation, Water, and 

Air Handling Systems 

This CD-ROM is intended to support the creation of 

training courses on Good Manufacturing Practices 

(GMP), particularly courses for inspectors of manufacturing 

facilities which produce medicines or pharmaceutical 

starting materials. The CD-ROM may also be 

useful as a self-study guide for the inspectors themselves, 

or anyone else interested in the manufacture 

of quality medicines. The content of the CD-ROM is 

based on a modular training course designed by staff 

of the World Health Organization in collaboration 

with a team of international experts in the subject. 

Details of the project that produced this course are 

to be found on the CD-ROM itself (in two formats - 

Microsoft Word and Adobe Acrobat, in the files 

'IntroAckn.doc' and 'IntroAckn.pdf' respectively, in the 

'Project' folder). There are twenty modules in the 

course. Fourteen of these cover Basic Principles of 

GMP, five cover the GMP Inspection Process, and the 

final module covers setting up and running a training 

course on GMP. The CD-ROM contains a set of the 

Microsoft PowerPoint presentations, together with 

handouts and other supporting material (these latter 

again in both Word and Acrobat formats), together 

with utilities for viewing or printing these. The CD- 

ROM also contains a software tool (installed by running 

'Setup') to help trainers modify the course to 

better fit local conditions and regulations. This contains 

the full text of the presentations in a searchable 

database, together with examples of speaker's notes, 

and action-setting and note-taking facilities, and 

options for printing these. The tool also provides 

access to an introductory video on GMP, which lasts 

18 minutes and has been optimised for viewing 

on-screen. 

The Supplementary Training Modules on Good 

Manufacturing Practices (GMP) are a product of the 

WHO/EDM Strengthening of Pharmaceutical 

Manufacturing Inspection (SPMI) Project. The aims 

of the project were to strengthen pharmaceutical 

manufacturing inspectorates by promoting the use 

of the previously developed training package entitled: 

WHO Basic Training Modules on GMP, through the 

setting up of international workshops using the 

materials, and by undertaking global distributions 

of the Basic Training Modules CD-ROM, issued in 

April 2001. The SPMI project concluded at the end 

of March 2003. 

In response to the many requests that were received 

back from individuals who had either attended a 

workshop or who had used the CD-ROM, three 

supplementary modules were developed on topics that 

had been specifically asked for, namely: 

• Validation (including Cleaning, Process, 

and QC-related Validation) 

• Water for Pharmaceutical Use, and 

• Air Handling Systems. 

The materials, which comprise PowerPoint slide 

presentations, tutorial notes, group session exercises, 

and question and answer papers, are intended to 

support the creation of training courses primarily 

for government compliance officers who inspect 

manufacturing facilities that produce medicines or 

pharmaceutical starting materials. The training 

package may also be useful as a self-study guide 

for these inspectors, or anyone else interested in the 

manufacture of quality medicines. 

15 

2001, CD-ROM [E] 

WHO/EDM/QSM/2000.7 

Available Free of Charge 

Order no. 1990012 

2003, CD-ROM [E] 


Available Free of Charge 

Order No. 1992012






16 

The Use of Common Stems in the Selection 

of International Nonproprietary Names 

(INN) for Pharmaceutical Substances 

2003 

Lists common stems for international nonproprietary 

names (INN) for pharmaceutical substances for which 

chemical or pharmacological categories have been 

established. These stems and their definitions are 

intended to guide the selection of new INNs (generic 

names) for substances that belong to an established 

series of related compounds. The list aims to encourage 

consistency in the designation of generic drug names 

while also protecting the principle that INNs are public 

property. Produced as a working document, the list is 

of interest to manufacturers engaged in research and 

development, trademark officers, and national regulatory 

authorities. 

2003, 137 pp, WHO/EDM/QSM/2003.2 

Electronic access: http://www.who.int/medicines/ 

library/qsm/stemdoc2002.pdf 

International Nonproprietary Names (INN) 

for Pharmaceutical Substances: Names of 

Radicals and Groups 

Comprehensive List April 2002 

Provides a comprehensive list of names for radicals and 

groups used in the WHO system for assigning international 

nonproprietary names (INNs) for pharmaceutical 

substances. Names for radicals and groups arise from 

the need to provide modified names for the salts or 

esters of substances already identified by an INN. In 

view of the complex composition of many radicals and 

groups, use of chemical nomenclature is inconvenient 

and shorter nonproprietary names are thus selected. 

The list also includes reference to two-word INNs. 

2003, 38 pages, WHO/EDM/QSM/2003.1 

Electronic access: http://www.who.int/medicines/ 

library/qsm/radicaldoc2002.pdf 

The Importance of Pharmacovigilance 

Safety Monitoring of Medicinal <strong>Products</strong> 

This document presents a critical examination of the 

strengths and weaknesses of present systems of safety 

monitoring in order to increase their impact, and provides 

an overview of the challenges facing pharmacovigilance 

in the future. 

2002, 48 pages 

ISBN 92 4 159015 7 

Electronic access: http://www.who.int/medicines/library/ 

qsm/ip_booklet.pdf 

Pharmaceuticals: Restrictions 

in Use and Availability 

2003, 26 pages [E] 



qsm/who-edm-qsm-99-2/who_edm_qsm_992.htm 

Safety of Medicines 

A Guide to Detecting and Reporting Adverse 

Drug Reactions 

2002, 18 pages [E] 



qsm/who-edm-qsm-2002-2/esd_safety.pdf 

Medical <strong>Products</strong> and the Internet 

A Guide to Finding Reliable <strong>Information</strong> 

As the medical information and the number of medical 

products for sale on the Internet increases rapidly, WHO 

has produced this guide to finding reliable medical 

information on the Net. 

1999, 16 pages 


Electronic access: http://www.who.int/medicines/library/qsm/ 

who-edm-qsm-99-4/who-edm-qsm-99-4.htm 

Counterfeit Drugs 

Guidelines for the Development of Measures 

to Combat Counterfeit Drugs 

In the recent past, the unregulated proliferation of pharmaceutical 

industries and products has brought with it 

many problems. These guidelines provide an overview 

of the problem of counterfeiting and the contributing 

factors. 

1999, 60 pages [E, F] 


Electronic access: http://www.who.int/medicines/library/qsm/ 

who-edm-qsm-99-1/who-edm-qsm-99-1.htm 

Safety Monitoring of Medicinal <strong>Products</strong> 

Guidelines for setting up and running a 

Pharmacovigilance Centre 

This booklet aims to provide practical guidelines 

and information for the setting up of new 

Pharmacovigilance Centres. It discusses practical 

aspects of how to run a pharmacovigilance centre 

at the technical level and provides many realistic 

recommendations. 

2000, 24 pages 

ISBN 91 630 9004 X 

Electronic access:http://www.who-umc.org/pdfs/guidelines.pdf


INTERNATIONAL PHARMACOPOEIA 

Now 

Available 

The International 

Pharmacopoeia 

Third Edition 

Volume 5: Tests and General Requirements for Dosage Forms. 

Quality Specifications for Pharmaceutical Substances 

and Dosage Forms. 

Presents an historical account of the Pharmacopoeia and describes 

methods and procedures for the quality control of pharmaceutical 

substances and dosage forms, including a special section on quality 

control of anti-malarials. 

Contents 

Preface. History. Acknowledgements. General Notices. 

Abbreviations and symbols. Tests, methods, and general requirements. 

Monographs for pharmaceutical substances. Monographs for tablets. 

Monographs for antimalarial drugs. List of reagents, test solutions, and 

volumetric solutions. Amendements and corrigenda to Volumes 1, 2, 3, and 4. 

Supplementary information. Index. Tests, methods, and general requirements. 

General requirements for dosage forms 

Ophthalmic preparations. Requirements for specific types of ophthalmic 

preparations. Suppositories. 

Tests for dosage forms 

Disintegration test for suppositories. Dissolution test for solid oral dosage 

forms. Test for extractable volume for parenteral preparations. Microbial purity 

of pharmaceutical preparations. Test for bacterial endotoxins. Test for sterility 

of non-injectable preparations. Visual inspection of particulate matter injectable 

preparations. 

17 

Monographs for pharmaceutical 

substances (Latin names) 

Albendazolum. Alcuronii chioridum. 

Amoxicillinum trihydricum. Atenololum. 

Benznidazolum. Benzoylis peroxidum cum 

aqua. Captoprilum. Chlorali hydras. 

Chloramphenicoli natrii succinas. 

Ciclosporinum. Ciprofloxacini 

hydrochlo-ridum. Ciprofloxacinum. 

Clindamycini phosphas. 

Dacarbazinum. Diethyltoluamidum. 

Dinitrogeniioxidum. Dithranolum. 

Erythromycini lacto bionas. Etoposidum. 

Heparinum calcicum. Heparinum 

natricum. Idoxuridinum. Isosorbidi dinitras 

dilutus. Ketoconazolum. Levamisoli 

hydrochloridum. DL-Methioninum. 

Methylrosanilinii chloridum. Metronidazoli 

benzoas. Nifedipinum. Nonoxinolum 9. 

Oxygenium. Prednisoloni natrii phosphas. 

Protamini sulfas. Retinolum densatum 

oleosum. Selenii disulfidum. 

Sulfadiazinum argentum. Tropicamidum. 

Monographs for tablets 

(Latin names) 

Allopurinoli compressi. Carbamazepini 

compressi. Codeini phosphatis compressi. 

Colchicini compressi. Dexamethasoni compressi. 

Diloxanidi furoatis compressi. 

Doxycyclini hyclatis compressi. 

Erythromycini ethylsuccinatis compressi. 

Erythromycini stearatis compressi. 

Ethambutoli hydrochoridi compressi. 

Ibuprofeni compressi. Indometacini compressi. 

Isoniazidi compressi. Morphini 

sulfatis compressi.Pethidini hydroch1oridi 

compressi. Phenobarbitali compressi. 

Phenytoini natrici compressi. Praziquanteli 

compressi. Prednisoloni compressi. Pyranteli 

embonatis compressi 

Monographs for antimalarial drugs 

(Latin names) 

Artemetherum. Artemetheri capsulae. 

Artemetheri compressi.Artemetheri injectio. 

Artemisininum. Artemisinini capsulae. 

Artemisinini compressi. Artemotilum. 

Artemotili injectio. Artenimolum. Artenimoli 

compressi. Artesunatum. Artesunati compressi. 

Mefloquini hydrochloridum. 

Proguanili hydrochloridum. 

Supplementary information 

Annotated references. List of available 

Intemational Chemical Reference Substances, 

list of available Intemational Infrared 

Reference Spectra. General guidelines for 

the establishment, maintenance, and distribution 

of chemical reference substances 

VOLUME 5 

2003, 389 pages [E, F*, S*] 

ISBN 92 4 154536 4 



Order no. 1155091 

New: Volume 5




Pharmacopoeia 


Volume 1: General 

Methods of Analysis 


Pharmacopoeia 


Volume 2: Quality Specifications 

18 

Describes methods and procedures 

for the quality control of pharmaceutical 

substances and dosage forms. 

“... a very useful laboratory aid...” 

— International Journal of Crude Drug 

Research 


Preface. General notices. Units of 

measurement 

Physical methods 

Measurement of mass. Determination 

of melting temperature, melting 

range, congealing point, boiling 

point, and boiling range. 

Determination of mass density 

and relative density. Determination of 

optical rotation and specific rotation. 

Determination of refractive index. 

Spectrophotometry in the visible and 

ultraviolet regions.Spectrophotometry 

in the infrared region. Atomic absorption 

spectrophotometry. Fluorescence 

spectrophotometry. Turbidimetry and 

nephelometry. Colour of liquids. 

Radiopharmaceuticals. Powder fineness 

and sieves. 

Physiochemical methods 

Chromatography. Determination of 

pH. Electrophoresis. Phase solubility 

analysis. 

Chemical methods 

General identification tests. Limit test 

for chlorides. Limit test for sulfates. 

Limit test for heavy metals. Limit test 

for iron. Limit test for arsenic. 

Sulfated ash. Oxygen flask method. 

Complexometric titrations. 

Non-aqueous titration. Nitrite titration. 

Determination of water by the 

Karl Fischer method. Determination 

of methoxyl. Determination of nitrogen. 

Determination of iodine value. 

Determination of peroxides in fixed 

oils. Determination of saponification 

value. Determination of unsaponifiable 

matter. Determination of acid 

value. 

Biological methods 

Microbiological assay of antibiotics. 

Sterility testing of antibiotics. Undue 

toxicity. Test for pyrogens. Test for 

histamine-like substances (vasodepressor 

substances). 

Methods for pharmacognosy 

Determination of ash and acidinsoluble 

ash. 

Miscellaneous 

International chemical reference 

substances. Names, symbols, and 

relative atomic masses of elements. 

List of reagents, test solutions, and 

volumetric solutions. Index. 

Contains quality specifications 

for 126 pharmaceutical substances 

included in the WHO Model List of 

Essential Drugs. The specifications 

are especially suited to quality 

control in developing countries. 

“... deserves due international 

recognition as a basis for 

standardising drug quality control 

procedures...” 

— The Pharmaceutical Journal 


Preface.General notices.Monographs. 

List of reagents, test solutions, and 

volumetric solutions. Index. 


Pharmacopoeia 


Volume 3: Quality Specification 

Presents quality specifications for 157 

widely used pharmaceutical sustances. 

In keeping with the overall purpose of 

the International Pharmacopoeia, the 

monographs are based on sound, 

classical chemical methods appropriate 

for use in small and medium-sized 

laboratories. 

“... helps enhance the applicability 

of the Pharmacopoeia to a large 

range of laboratory settings...” 

— Journal of Pharmacy Technology 


Preface. Acknowledgements. 

Monographs. List of reagents, test 

solutions, and volumetric solutions. 

Amendements and corrigenda to 

Vols. 1 and 2. Index. 

Volume 1 

1979, 223 pages [E, F, S] 

ISBN 92 4 154150 4 


In developing countries: Sw.fr.16.80 

Order no. 1151091 

Volume 2 

1981, 342 pages [E, F, S] 

ISBN 92 4 154151 2 



Order no. 1152091 

Volume 3 

1988, 407 pages [E, F, R, S] 

ISBN 92 4 154215 2 



Order no. 1153091 

“global drug quality control”




Volume 4: Tests, Methods, 

and General Requirements; 

Quality Specifications for Pharmaceutical 

Substances, Excipients, and Dosage 

Forms 

Provides a collection of recommended quality 

specifications and methods of analysis for 

selected pharmaceutical products, excipients, 

and dosage forms. 


Preface. Acknowledgements. General Notices. 

Abbreviations and symbols. Tests, methods, 

and general requirements. Monographs for 

pharmaceutical substances. Monographs for 

excipients. Monographs for dosage forms. 

List of reagents, test solutions, and volumetric 

solutions. Amendements and corrigenda to 

Volumes 1, 2, and 3. Index.Tests, methods, 

and general requirements. Test for sterility, 

Methods of sterilization, Atomic emission and 

absorption spectrometry. 

General requirements for substances 

Hydroxyl value 

General requirements for dosage forms 

Tablets, capsules, parenteral preparations, 

disintegration test for tablets and capsules. 

Topical semi-solid dosage forms. Uniformity 

of content for single-dose preparations. 

Uniformity of mass for single-dose preparations. 


Pharmacopoeia 

CD-ROM 

Now available 

This multilingual CD-ROM contains all 

5 volumes of the International Pharmacopoeia 

in English and volumes 1-4 in French and 

Spanish. 

The user-friendly interface allows searches 

to be conducted by volume, monograph 

(substances,monographs for excipients, 

monographs for dosage forms), general 

methods or reagents. 

19 

Volume 4 

1994, xv + 343 pages [E, F, S] 

ISBN 92 4 154462 7 



Order no. 1154091 

CD-ROM [E/F/S] 

2003 

ISBN 92 4 056021 1 



Order no. 0990020




“your benchmark to global drug quality control” 

30% 

DISCOUNT 

Special price offer for 5 volumes: 

Swiss francs 212.80 / US $191.00 

In developing countries Swiss francs 148.– 

CD-ROM 

ALSO 

AVAILABLE 

Order Form 

MDI.PHS.203 

20 

Please send me copies of The International Pharmacopoeia, special price offer for 5 volumes at the price 

of Swiss francs 212.80 / US $191.00; in developing countries Swiss francs 148.– 

Please send me The International Pharmacopoeia : 

copies of volume 1 at the price of Swiss francs 24.– / in developing countries Swiss francs 16.80 (order no. 1151091) 





copies of International Pharmacopoeia CD-ROM at the price of Swiss francs 150.– /in developing countries 

Swiss francs 105.– (order no. 0990020) 

Name 

Address 

Postal code City Country 

Tel. Fax Email 

Payment enclosed 

Please charge to my credit card 

Visa American Express Diners Club Eurocard/Access/Mastercard 

My credit card number is: 

Expiry date: Date of order: Signature: 

Please return or fax this order to: 

WHO - Marketing & Dissemination 

1211 Geneva - 27 Switzerland 

Tel. +41 22 791 24 76 Fax +41 22 791 48 57 

Email: bookorders@who.int 

Order online at: http//:bookorders.who.int 

For customers in the USA, please return or fax this order to: 

WHO Publications Center USA 

49 Sheridan Avenue 

Albany NY 12210, USA 

Tel. +518 436-9686 Fax +518 436 7433 

Email: qcorp@compuserve.com


DRUG PRESCRIBING 






Adherence to Long-term 

Therapies 

Evidence for Action 

Adherence to therapies is a primary 

determinant of treatment success. 

Poor adherence attenuates optimum 

clinical benefits and therefore 

reduces the overall effectiveness of 

health systems. 

"Medicines will not work if you do 

not take them". Medicines will 

not be effective if patients do not 

follow prescribed treatment, yet in 

developed countries only 50% of 

patients who suffer from chronic 

diseases adhere to treatment recommendations. 

In developing countries, 

when taken together with poor 

access to health care, lack of appropriate 

diagnosis and limited access 

to medicines, poor adherence is 

threatening to render futile any 

effort to tackle chronic conditions, 

such as diabetes, depression and 

HIV/AIDS. 

This report is based on an exhaustive 

review of the published literature 

on the definitions, measurements, 

epidemiology, economics and 

interventions applied to nine chronic 

conditions and their risk factors. 

These are asthma, cancer (palliative 

care), depression, diabetes, epilepsy, 

HIV/AIDS, hypertension, tobacco 

smoking and tuberculosis. 

Intended for clinical practitioners, 

health managers and policy-makers, 

this report provides a concise 

summary of the consequences of 

poor adherence for health and 

economics. 

Guide to Good Prescribing 

A Practical Manual 

A spiral-bound training manual 

offering a step-by-step guide 

to the process of rational, responsible 

prescribing. Addressed to 

undergraduate medical students 

who are about to enter the 

clinical phase of their studies, 

the manual aims to help students 

acquire the skills and confidence 

needed to exercise independent 

judgement and make their own 

decisions about which drugs or 

non-drug treatments are best 

for each individual patient. 

Throughout, numerous practical 

exercises and examples of patients 

and their complaints are used to 

help tie advice to the realities of 

a doctor’s daily practice. 

Teacher’s Guide to Good 

Prescribing 

This is a companion volume to the 

Guide to Good Prescribing. Its target 

audience is university teachers 

who wish to use the Guide for 

teaching undergraduate medical 

students. 

2001, 106 pages 



medicines/library/par/teachers 

_guide.pdf 

21 

2003, 212 pages [E] 

ISBN 92 4 154599 2 

Swiss francs: 30.–/US $27.00 


Order no. 1150526 

by T.P.G.M. de Vries, R.H. Henning, 

H.V. Hogerzeil and D.A. Fresle 

1995, ii + 108 pages [E, F, S, C, G, P] 

WHO/DAP/94.11 



Order no. 1930074



WHO Model Prescribing <strong>Information</strong>: 

Drugs Used in Parasitic Diseases 


WHO Model Prescribing <strong>Information</strong>: 

Drugs Used in Sexually Transmitted 

Diseases and HIV Infection 

22 

The second revised edition of model prescribing 

information for some 37 essential drugs used for 

the prevention and treatment of protozoal and 

helminthic infections. The sections on malaria, African 

trypanosomiasis, cestode infections, schistosomiasis, and 

onchocerciasis have been extensively revised in the light 

of new developments in the treatment of these 

diseases. 

The book is organized according to diseases, moving 

from amoebiasis and giardiasis to intestinal, liver, and 

lung flukes. Each disease or group of diseases is first 

introduced with concise information about its causes, 

mode of transmission, clinical features, and geographical 

prevalence, followed by general advice on prevention 

and treatment. Prescribing information is then 

provided for first-choice and alternative therapeutic and 

prophylactic drugs. <strong>Information</strong> includes uses, dosage 

and administration, contraindications and precautions, 

use in pregnancy, adverse effects, drug interactions, 

and advice on storage. 

From reviews of the first edition: 

"... a mine of admirably concise and accurately 

compiled data ... will be of enormous value..." 

– Transactions of the Royal Society of Tropical Medicine 

and Hygiene 

A practical guide to the use of drugs in the management 

of sexually transmitted diseases and diseases 

associated with HIV infection. Addressed to clinicians, 

especially in developing countries, the book aims to 

guide the selection and prescribing of drugs in line 

with the latest knowledge about efficacy, safety, and 

costs. <strong>Information</strong> responds to both the dramatic 

global increase in the incidence of these diseases 

and the spread of resistance to readily available 

antimicrobials. 

1995, 146 pages [E, F, S] 

ISBN 92 4 140104 4 



Order no. 1152343 

1995, 97 pages [E, F, S] 

ISBN 92 4 140105 2 



Order no. 1150429


WHO Model Prescribing 

<strong>Information</strong>: Drugs Used 

in Skin Diseases 

WHO Model Prescribing 

<strong>Information</strong>: Drugs Used 

in Bacterial Infections 

Guide to Chemotherapy 

and Chemoprophylaxis 

in Bacterial Infections 

Second Edition 

Provides model prescribing information 

for essential drugs used in 

the treatment of skin diseases. 

Emphasis is placed on skin diseases 

commonly found in developing 

countries, since rural communities 

in these areas continue to experience 

considerable disability, disfigurement, 

and distress caused by 

curable or controllable diseases. 

Some rare but life-threatening 

disorders, such as pemphigus, are 

also briefly discussed. 

Provides model prescribing information 

for essential drugs used 

in the treatment of bacterial 

infections. This new volume 

includes drugs used for treating 

respiratory, gastrointestinal, urinary, 

perioral, dental and cardiovascular 

infections, as well as septicaemia 

and infections of the skin, soft 

tissues, bones and joints, sexually 

transmitted diseases, and other 

commonly encountered bacterial 

infections. It also covers prophylaxis 

against rheumatic fever, meningitis, 

and bacterial infection during 

surgery. 

This guide aims to provide a comprehensive 

yet simplified approach 

to the rational use of antibiotics 

and to help the physician select 

therapeutic programmes that 

are both safe and effective. This 

second edition updates a number 

of recommendations as a result of 

new developments and emergence 

of resistance in bacterial infections. 

23 

1997, iv + 126 pages [E, F, S, R] 

ISBN 92 4 140106 0 



Order no. 1150450 

2001, iv + 126 pages [E] 

ISBN 92 4 140107 9 



Order no. 1150483 

WHO Regional office for the Eastern 

Mediterranean 

Eastern Mediterranean Series, No. 4 

1997, 134 pages [E] 

ISBN 92 9021 225 X 



Order no. 1442004



Antimicrobial Resistance 

in the Americas 

Magnitude and Containment 

of the Problem 

Drugs for the Elderly 


Vitamin A Supplements 

A Guide to their Use in the 

Treatment and Prevention 

of Vitamin A Deficiency and 

Xerophthalmia 


24 

This book makes a valuable contribution 

to the surveillance of resistance 

to antibiotics. The text offers 

noteworthy articles grouped under 

two major categories: monitoring 

bacterial resistance to antimicrobial 

drugs, and factors determining the 

use of antimicrobials. The goal of 

this work is to increase awareness 

of the problem, to promote surveillance 

activities, and to find the best 

ways to apply preventive measures, 

so that antibiotics are used judiciously 

with both humans and 

animals. 

The second revised edition of a 

popular practical guide to the prescribing 

of drugs for the elderly. 

Designed to promote a more 

rational use of drugs, the book 

emphasizes the many physical and 

mental conditions associated with 

aging that must be considered 

when evaluating symptoms and 

selecting the most appropriate 

drug, dose, and formulation. 

Provides concise, authoritative 

advice on the use of high-dose 

vitamin A supplements for the 

control of vitamin A deficiency and 

the emergency treatment of 

xerophthalmia and other conditions 

in high-risk groups. Now in its 

second edition, the guide has been 

updated to reflect the latest 

scientific knowledge, particularly 

concerning the safety and effectiveness 

of different dose schedules 

in different age and population 

groups. 

Pan American Health Organization 

by R. Salvatierra-González and 

Y. Benguigui 

2001, 269 pages [E] 

ISBN 92 75 32319 5 

Swiss francs: 50.–/ US $ 45.00 


Order no. 1630121 

WHO Regional office for Europe 

WHO Regional Publications, 

European Series, No. 71 

1997, x + 145 pages [E] 

ISBN 92 890 1335 4 



Order no. 1310071 

1997, vi + 28 pages [E, F, S] 

ISBN 92 4 154506 2 



Order no. 1152303


LEGISLATION AND REGULATION 

International Travel 

and Health 2003 

Situation as on 1 January 2003 

Effective Drug Regulation 

A Multicountry Study 

Guidelines for the 

Regulatory Assessment 

of Medicinal <strong>Products</strong> 

for Use in Self-medication 

This edition of International 

travel and health was completely 

redesigned in 2002 to reflect better 

knowledge about the risks to 

which travellers are exposed and 

the precautions needed to protect 

their health. 

The book offers guidance on the 

full range of health risks likely to 

be encountered at specific destinations 

and associated with different 

types of travel - from business, 

humanitarian and leisure travel to 

backpacking and adventure tours. 

<strong>Information</strong> is intended to help the 

medical profession be fully alert to 

potential risks and provide appropriate 

advice, whether concerning 

recommended vaccinations, protection 

against insects and other disease 

vectors, or safety in different 

environmental settings. <strong>Information</strong> 

on infectious diseases of potential 

risk for travellers has also been 

greatly expanded. Additional chapters 

describe vaccine-preventable 

diseases, vaccines for routine and 

selective use, and selection criteria, 

and offer detailed guidance 

on malaria, the most important 

infectious disease threat for 

travellers. 

Drugs play a crucial role in saving 

lives, restoring health, and preventing 

diseases and epidemics. But 

they need to be safe, efficacious, 

of good quality, and used rationally. 

This means that their production, 

import/export, storage, supply and 

distribution should be subject to 

government control through prescribed 

norms and standards and 

an effective regulatory system. 

Substandard and counterfeit drugs 

proliferate primarily in an environment 

where drug regulation has 

proved ineffective. 

This publication presents a 

synthesis of studies on drug 

regulation carried out in 10 

countries: Australia, Cuba, Cyprus, 

Estonia, Malaysia, the Netherlands, 

Tunisia, Uganda, Venezuela, and 

Zimbabwe in 1998-1999. It gives 

an overview of the development of 

drug regulation in these countries 

as well as the resources available 

and the strategies applied in drug 

regulation implementation at the 

time the studies were conducted. 

An analysis of the strengths and 

weaknesses in drug regulation in 

these countries is also provided. 

Presents guidelines for determining 

when medicinal products, sold on 

prescription only, can be reclassified 

for non-prescription, or over-thecounter, 

sale. Noting that self-medication 

plays an important role in 

the health care system, the booklet 

sets out criteria and methods 

intended to help drug regulatory 

authorities decide when a product 

is suitably safe and effective for 

self-medication. 

25 

2002, vii + 85 pages [E, F] 

ISBN 92 4 158028 3 



Order no. 1180003 

by S. Ratanawijitrasin and 

E. Wondemagegnehu 

2002, ix + 189 pages [E] 

ISBN 92 4 156206 4 



Order no. 1150503 

2000, 31 pages [E] 




Order no. 1930175


LEGISLATION AND REGULATION 

Marketing Authorization 

of Pharmaceutical <strong>Products</strong> 

with Special Reference 

to Multisource (Generic) 

<strong>Products</strong> 

A Manual for a Drug 

Regulatory Authority 

26 

A detailed guide to the establishement 

of a system for the marketing 

authorization of multisource (generic) 

pharmaceutical products. Addressed 

to drug regulatory authorities, the 

guidelines are intended for use in 

countries that do not presently have 

a fully functional system of premarket 

evaluation and market authorization, 

and want to establish such a system, 

giving priority to the assessment and 

authorization of generic drugs. 

Regulatory Support Series, No. 5 

1999, v + 213 pages [E] 

WHO/DMP/RGS/98.5 



Order no. 1930169


PUBLICATIONS FROM THE SOUTH CENTRE 

Publications from 

The South Centre 

The South Centre is an intergovernmental organization 

based in Geneva. (For details about the South Centre visit 

its website www.southcentre.org ) It undertakes policyoriented 

analytical work on issues of common interest to 

the countries and peoples of the South. The Centre functions 

essentially as an intellectually autonomous think-tank. 

While the Centre is very small and has very limited financial 

resources at its disposal, its strength is based on networking 

with institutions and experts in the South. Its political and 

substantive relevance and importance stems from its mandate 

to promote South solidarity and consciousness; to promote 

various types of South-South cooperation and action, 

links, networking and information exchange; to contribute 

to efforts to coordinate participation by developing countries 

in international forums dealing with South-South and 

North-South matters and to foster convergent views and 

approaches among countries of the South – with respect 

to global economic, political and strategic issues related 

to development, sovereignty, security and in general 

governance and direction of the international system. 

The scope of Centre’s work and activities ranges over a 

broad spectrum. Among other things, it has done work on 

South-South cooperation, UN reform, financing and development, 

sustainable development, intellectual property, and 

international trade, and has produced policy papers and 

publications on the occasion of major UN conferences, 

most recently those held in Monterrey on financing 

for development and in Johannesburg on sustainable 

development. An area where the Centre has been able to 

undertake more systematic and sustained activity thanks 

to the availability of project funding has to do with WTO, 

trade and development. 

While the Centre has not as yet initiated a work programme 

on health-related matters, it has worked in close 

contact with WHO, especially its Department of Essential 

Drugs and Medicines Policy, and has issued a number of 

relevant publications, including joint publications with 

WHO, most recently a study entitled Protection and 

Promotion of Traditional Medicine: Implications for Public 

Health in Developing Countries. The Centre plans, as its 

resources and staffing expand, to initiate systematic work 

on health-related issues from a South perspective. 

27 

Contact address: South Centre, BP 228, 17-19 

Chemin du Champ d’Anier, 1211 Geneva 19, Switzerland. 

Tel 41-22-7918050, Fax 41-22-7988531, 

Email: south@southcentre.org


ETHICS AND SAFETY GUIDELINES 

Assessing New Vaccines 

for National Immunization 

Programmes 

A Framework to Assist 

Decision-makers 

Guidelines for Preparing Core 

Clinical-Safety <strong>Information</strong> 

on Drugs 


Including New Proposals for 

Investigator’s Brochures 

Report of CIOMS, Working 

Groups III (Revised) and V (New) 

Biomedical Research Ethics: 

Updating International 

Guidelines 

A Consultation 

28 

This book aims to help policy 

analysts and decision-makers 

when considering the addition 

of new vaccines to national 

immunization programmes. It 

reflects the growing international 

concerns that all children of the 

world should have access to 

life-saving vaccines wherever they 

happen to live, and provides a 

set of questions to work through 

the technical issues for adding 

a new vaccine to the national 

immunization schedule. 

A revised and expanded edition 

of the first internationally-agreed 

guidelines covering the minimum 

drug safety information that should 

be communicated by manufacturers 

to physicians and other prescribers. 

Originally published as the 

CIOMS Working Group III report, 

the "Core Safety <strong>Information</strong>" 

specified in the guidelines has been 

widely endorsed as a standard for 

the preparation of all official 

national data sheets, package 

inserts, product labels, and other 

official statements issued by 

manufacturers. 

The Guidelines, first issued in 1982 

and then revised in 1993, are being 

updated and expanded to address a 

number of new and especially challenging 

ethical issues. These include issues 

raised by international collaborative 

trials of drugs in developing countries, 

especially expansive drugs, and the use 

of placebo controls in randomized 

clinical trials. Others arise from the 

complexity of research in human 

genetics, including stem-cell research, 

and in reproductive biology. 

WHO Regional Office for the 

Western Pacific 

2000, v + 32 pages [E] 

ISBN 92 9061 154 5 

Swiss francs 10.–/US$9.00 


Order no. 1520015 

CIOMS, 1999, 98 pages [E] 

ISBN 92 9036 070 4 



Order no. 1840021 

Edited by R.J. Levine and 

S. Gorovitz with J. Gallagher 

CIOMS, 2000, viii + 295 pages [E] 

ISBN 92 9036 073 9 



Order no. 1840023


Benefit-Risk Balance for 

Marketed Drugs: Evaluating 

Safety Signals 

Report of CIOMS, Working 

Group IV 

Adverse Drug Reaction 

Terms: Definitions 

Respiratory Disorders, 

Skin Disorders 

Presents and explains a standardized 

methodology for reassessing the 

established benefit-risk relationship of 

a marketed drug when a new safety 

problem arises. Addressed to drug 

manufacturers and regulatory 

authorities, the book responds to the 

absence of any standard, systematic 

procedure for assessing newly detected 

hazards, balancing risks against 

benefits, and reporting the results. 

The recommended approach, which 

reflects the consensus reached by 24 

representatives of industry and 

government regulatory authorities, 

includes detailed advice on concepts 

and procedures for determining the 

magnitude of the safety problem and 

deciding on the appropriate action, 

whether involving a routine change 

in product information or immediate 

withdrawal of the drug from the 

market. The use of a standard 

reporting form, presented here for 

the first time, forms a central part 

of the recommended procedure. 

Provides concise definitions for 

twenty-six terms frequently used 

when reporting respiratory and 

skin disorders that may be caused 

by adverse reactions to drugs. 

Addressed to drug regulatory 

authorities and the drug safety 

units of pharmaceutical companies, 

the book responds to the problems 

created when spontaneous reports 

of adverse drug reactions use 

imprecise, incorrect, or inconsistent 

terms. With these problems in 

mind, the book sets out precise 

definitions of terms, and minimum 

requirements for their use, for the 

most important respiratory and skin 

disorders that may be caused by 

drugs. The book is part of an ongoing 

project to develop an internationally 

agreed terminology for 

the designation, reporting, validation, 

and coding of adverse drug 

reactions, giving priority to the 

most severe disorders that may 

be caused by drugs. 

29 


ISBN 92 9036 068 2 

Sw.fr. 15.–/US $13.50 


Order no. 1840020 


ISBN 92 9036 064 X 



Order no. 1840019


WHO COLLABORATING CENTRE FOR 

INTERNATIONAL DRUG MONITORING 

The WHO 

Collaborating Centre 

for International Drug Monitoring 

30 

This WHO Collaborating Centre is situated in Uppsala 

Sweden and known throughout the world as the 

Uppsala Monitoring Centre. 

The UMC supports WHO's leadership in the field 

of world health by providing excellence 

• in the science and concepts of all aspects of 

pharmacovigilance 

• to prevent harm to humans from the effects 

of medicines 

• to gather and share objective intelligence and 

opinion in the field of drug safety through open 

and transparent means of communication 

• to support the promotion of the rational use of 

drugs, and the achievement of improved 

patient therapy and public health 

• in global education and communications in benefit, 

harm, effectiveness and risk in medical therapy 

It achieves this by 

• developing leading-edge systems and science for 

the identification and communication of safety 

hazards in drugs and other substances used in 

medicine 

• carrying out research pushing forward the ethical, 

intellectual and scientific boundaries of theory and 

practice in pharmacovigilance 

• pursuing active collaboration and communication 

with all stakeholders 

• pursuing the goal of a single, global database 

for drug safety data 

And in particular it aims to 

• ensure that effective, timely international collective 

effort will never miss a signal of a potential hazard 

• ensure that all stakeholders evaluate and learn 

from decisions and actions through positive 

impact-assessment, follow-up and debate 

• encourage the growth of pharmacovigilance 

activities around the world, in particular the 

establishment of new National Centres 

• promote existing National Centres and other stake 

holders in the field 

• to contribute actively to the global vision of the 

WHO Programme 

• to use and share available information openly 

and transparently 

• to sponsor and support others in their 

pharmacovigilance activities 

• to exploit fully the resources of the UMC 

• stimulate the development of coherent, harmonised 

systems worldwide for pharmacovigilance, through 

education, training, promoting and participating in 

international forums, the promotion of best practice 

and the publication of guidelines 

• maintain and develop useful products, services and 

tools in pursuit of the vision and goals of the WHO 

Programme and the UMC. 

Some key publications of the Uppsala 

Monitoring Centre are: 

• Viewpoint – Watching for Safer Medicines 

• Guidelines for setting up and running 

a Pharmacovigilance Centre 

• Pharmacovigilance in Focus 

• Uppsala Reports 

• Communicating Drug Safety <strong>Information</strong> - 

The Erice Declaration 

• Dialogue in Pharmacovigilance - more effective 

communication 

• Expecting the Worst –Anticipating, preventing and 

managing medicinal product crises 

• Guidelines for Herbal ATC classification 

• National Pharmacovigilance Systems 

• The WHO Adverse Reaction Terminology 

• The WHO Drug Dictionary 

For further information and publication orders, 

please contact: 

WHO Collaborating Centre for International 

Drug Monitoring 

Stora Torget 3 

S-753 20 Uppsala, Sweden 

Tel: +46-18-656060 

Fax: +46-18656080 

Email: info@who-umc.org 

web site: www.who-umc.org


MEDICINAL PLANTS 

Guidelines for the 

Appropriate Use 

of Herbal Medicines 

Research Guidelines for 

Evaluating the Safety and 

Efficacy of Herbal 

Medicines 

Some Traditional Herbal 

Medicines, Some Mycotoxins, 

Naphthalene and Styrene 

Reports the findings and recommendations 

of a working group 

convened to prepare guidelines 

for the use of herbal medicines 

in Western Pacific countries. 

Addressed to national health 

authorities, the report responds to 

the widespread use of herbal medicines 

in this part of the world and 

the corresponding need for mechanisms 

to ensure that these products 

are safe and effective, yet remain 

broadly accessible. With this need in 

mind, the report sets out a comprehensive 

framework for developing 

national policies designed to control 

the safety, efficacy, and quality of 

herbal medicines, manufacturing 

practices, product registration, 

and labelling, marketing, and trade. 

Sets out detailed guidelines for 

conducting scientific research on 

the safety and efficacy of herbal 

medicines. The guidelines, which 

reflect the consensus reached by 

17 experts in pharmacology, 

biochemistry, and traditional 

medicine, respond to the need to 

assure the safety of widely-used 

herbal medicines while also 

facilitating the search for new 

pharmaceutical products. Specific 

research criteria are covered 

together with general principles 

of investigation, including ethical 

concerns. 

Traditional herbal medicines 

encompass an extremely diverse 

group of preparations that originate 

from many different cultures. 

In recent years, such products have 

become widely available commercially 

in developed countries, where 

mixtures prepared from medicinal 

plants have been marketed or uses 

that were never contemplated in the 

traditional healing systems from 

which they emerged. 

This monograph evaluates the 

carcinogenic risks to humans posed 

by the use of some traditional 

herbal medicines, Fumonisin B1, 

and the industrial organic chemicals 

naphthalene and styrene, and 

provides an update of the data on 

the carcinogenicity of aflatoxins. 

An Annex to the volume describes 

fungal sources and formation of 

aflatoxins in foods and feeds, and 

discusses practical strategies for 

reduction of aflatoxin levels. 

31 

WHO Regional Office for the Western Pacific 

WHO Regional Publications, Western Pacific 

Series, No. 23 

1998, vi + 79 pages [E] 

ISBN 92 9061 124 3 

Swiss francs 7.50/US $6.70 


Order no. 1510023 

WHO Regional Office 


1993, v + 86 pages [E] 

ISBN 92 9061 110 3 

Swiss francs 7.50/US $6.70 


Order no. 1520003 

International Agency 

for Research on Cancer 

IARC Monographs on the Evaluation 

of Carcinogenic Risks to Humans, 

Volume 82 

2002, 500 pages [E] 

ISBN 92 832 1282 7 



Order no.1720082



Medicinal Plants in China 

Medicinal Plants in Viet Nam 

Medicinal Plants 

in the Republic of Korea 

<strong>Information</strong> on 150 commonly 

used Medicinal Plants 

32 

Catalogues the 150 species of 

medicinal plants most commonly 

used in traditional Chinese 

medicine. Each plant species is first 

documented by a full colour photograph 

taken under natural conditions 

during the flowering or 

fruiting season. Where relevant, 

a second photograph illustrates the 

plant parts from which the crude 

drug is extracted. Explanatory notes 

for each species cover botanical 

name and synonyms, Chinese 

name, English name, parts used, 

description of the plant, its habitat, 

and geographical distribution, and 

clinical indications and dosage. 

Some of the syndromes and clinical 

signs are described in traditional 

Chinese medical terminology. 

<strong>Information</strong> on indications and 

dosage is in keeping with theories 

for the prescription of medicinal 

plants taken from traditional 

Chinese pharmacology. 

Catalogues the 200 species of 

medicinal plants most commonly 

used in traditional Vietnamese 

medicine. The book, which has 

been translated from the original 

Vietnamese, was produced in an 

effort to communicate knowledge 

about herbal medicine that has 

accumulated over thousands of 

years, has been confirmed through 

both empirical experience and 

scientific evaluation, and yet has 

rarely been published outside the 

Vietnamese literature. The book 

also responds to increasing respect 

for the value of medicinal plants as 

a source of efficacious and inexpensive 

new drugs that offer an 

important alternative to chemically 

synthesized medicines. 

Presents concise monographs, 

accompanied by full-colour photographs, 

for the 150 plant species 

most commonly used for medicinal 

purposes in the Republic of Korea. 

In view of the country's long and 

successful history in the use of traditional 

medicines, the book aims 

to provide written and visual documentation 

of important plants and 

summarize their uses to treat 

ailments, protect against disease, 

or promote health. 

WHO Regional office for the Western 

Pacific 


Western Pacific Series, No. 2 

1989, 327 pages, 

151 colour plates[E] 

ISBN 92 9061 102 2 



Order no. 1510002 

WHO Regional office for the Western Pacific 



1990, 410 pages, 200 colour plates [E] 

ISBN 92 9061 101 4 



Order no. 1510003 

Compiled by Natural <strong>Products</strong> Research 

Institute, Seoul National University 

WHO Regional office for the Western Pacific 



1998, ix + 316 pages, 150 colour plates [E] 

ISBN 92 9061 120 0 



Order no. 1510021


Medicinal Plants in the 

South Pacific 

<strong>Information</strong> on 102 commonly 

used Medicinal Plants in the 

South Pacific 

General Guidelines 

for Methodologies on 

Research and Evaluation 

of Traditional Medicine 

Describes the information available, 

from both traditional medical texts 

and recent scientific studies, for 

102 medicinal plants used in the 

South Pacific Islands. Plants from 

this part of the world represent an 

especially diverse flora and include 

several species currently undergoing 

scientific investigation. 

Addressed to ethnobotanists, 

phyto-chemists, and pharmacologists, 

the book aims to document 

traditional clinical uses and bring 

these to the attention of the 

international scientific community. 

WHO has developed these general 

guidelines in response to the question: 

what types of academic 

research approaches and methods 

can be used to evaluate the safety 

and efficacy of traditional medicine? 

The guidelines presented in this 

document consist of sections on 

herbal medicines, on traditional procedure-based 

therapies, on clinical 

research, and related issues including 

ethics, education and training, 

and surveillance systems. 

The specific objectives of the guidelines 

are to harmonize the use of 

certain accepted and important 

terms in traditional medicine; summarize 

key issues for developing 

methodologies for research and 

evaluation of traditional medicine; 

improve the quality and value of 

research in traditional medicine; and 

provide appropriate evaluation 

methods to facilitate the development 

of regulation and registration 

in traditional medicine 

33 

WHO Regional office 




1998, xvii + 254 pages, 102 colour plates [E] 

ISBN 92 906 1119 7 



Order no. 1510019 

2001, vi + 71 pages [E, F*] 

WHO/EDM/TRM/2000.1 



Order no. 1930184



WHO Monographs on Selected 

Medicinal Plants, Volume 1 





IN PREPARATION 

34 

This book contains 28 monographs 

on widely used medicinal plants, 

selected for inclusion on the basis 

of scientific evidence for both safety 

and efficacy. Each monograph 

contains two parts, the first of 

which provides pharmacopoeial 

summaries for quality assurance 

purposes, including botanical features, 

identity tests, purity requirements, 

chemical assays and major 

chemical constituents. The second 

part, drawing on an extensive 

review of scientific research, 

describes the clinical applications 

of the plant material, with detailed 

pharmacological information and 

sections on contraindications, 

adverse effects and dosage. 

The monographs are intended to 

promote international harmonization 

in the quality control and use 

of herbal medicines and to serve 

as models for the development 

of national formularies. 

Volume 2 of the WHO Monographs on 

Selected Medicinal Plants provides an 

additional collection of 30 monographs 

covering the quality control and traditional 

and clinical uses of selected 

medicinal plants reviewed by 120 

experts in more than 50 countries. 

It follows the same format as Volume 1 

with the addition of two cumulative 

indexes in order to facilitate referencing. 

One lists the monographs in 

alphabetical order by plant name and 

the other according to the plant material 

of interest. Volume 2 also includes 

general technical notices that provide 

descriptions of each section. 

Provides an additional collection 

of 31 monographs. 

Medicinal Plants covered in volume 1 

Bulbus Allii Cepae. Bulbus Allii Sativi. 

Aloe. Aloe Vera Gel. Radix Astragali. 

Fructus Bruceae. Radix Bupleuri. 

Herba Centellae. Flos Chamomillae. 

Cortex Cinnamomi. Rhizoma 

Coptidis. Rhizoma Curcumae Longae. 

Radix Echinaceae. Herba Echinaceae 

Purpureae. Herba Ephedrae. Folium 

Ginkgo. Radix Ginseng. Radix 

Glycyrrhizae. Radix Paeoniae. Semen 

Plantaginis. Radix Platycodi. Radix 

Rauwolfiae. Rhizoma Rhei. Folium 

Sennae. Fructus Sennae. Herba 

Thymi. Radix Valerianae. Rhizoma 

Zingiberis. 


Radix Althaeae. 

Herba Andrographidis. 

Radix Angelicae Sinensis. Flos 

Calendulae. Flos Caryophylli. 

Rhizoma Cimicifugae. Folium 

cum Flore Crataegi. Radix 

Eleutherococci. Aetheroleum 

Eucalypti. Folium Eucalypti. 

Cortex Frangulae. Folium et 

Cortex Hamamelidis. 

Semen Hippocastani. 

Herba Hyperici. Aetheroleum 

Melaleucae. Folium Melissae. 

Aetheroleum Menthae 

Piperitae. Folium Menthae 

Piperitae. Folium Ocimi sancti. 

Oleum Oenotherae Biennis. 

Rhizoma Piperis Methystici. 

Cortex Pruni Africaniae. 

Cortex Rhamni Purshianiae. 

Flos Sambuci. Radix senegae. 

Fructus serenoae Repentis. 

Fructus silybi Mariae. 

Herba Tanaceti Parthenii. 

Radix Urticae. Folium Uvae Ursi. 


Fructus Ammi Majoris. Fructus 

Ammi Visnagae. Fructus Anethi. 

Aetheroleum Anisi. Fructus Anisi. 

Semen Armeniacae. Flos Arnicae. 

Folium Azadirachti.Oleum 

Azadirachti. Flos Carthami. 

Stigma Croci. Fructus Foeniculi. 

Radix Gentianae Luteae. Radix 

Gentianae Scabrae. Gummi 

Gugguli. Radix Harpagophyti. 

Rhizoma Hydrastis. 

Radix Ipecacuanhae. 

Aetheroleum Lavandulae. 

Flos Lavandulae. Strobilus Lupuli. 

Gummi Myrrha. Herba Passiflorae. 

Testa Plantaginis.Radix Rehmanniae. 

Fructus Schisandrae. Radix 

Scutellariae. Radix cum Herba 

Taraxaci. Semen Trigonellae 

Foenugraeci. Cortex Uncariae. 

Fructus Zizyphi. 

1999, v + 289 pages [E] 

ISBN 92 4 154517 8 



Order no. 1150460 

2002, v + 357 pages [E] 

ISBN 92 4 154537 2 



Order no. 1152460 

IN PREPARATION 2004 

Order no. 1153460


TRADITIONAL MEDICINE 

Regulatory Situation 

of Herbal Medicines 

A Worldwide Review 

The increasing demand for medicinal 

plants and the products derived 

from them has led to concerns 

over their safety and efficacy. 

The evaluation of herbal medicines 

and the use of registration and 

regulation to ensure their safety 

and efficacy present important 

challenges. 

This document describes experiences 

from 52 countries in 

formulating policies on herbal 

medicines and introducing 

measures for their regulation 

and registration. 

1998, 45 pages [ E, F, S] 

WHO/TRM/98.1 



Order no. 1930193 

Traditional Medicine in Asia 

This unique book provides a 

comprehensive picture of the vivid 

kaleidoscope of traditional 

medicine in Asia presented by 34 

eminent authors from 15 countries, 

belonging to the different systems 

like Ayurveda and Chinese 

Traditional Medicine. 

Important emerging areas such as 

harmonization of the traditional 

systems with modern medicine and 

the growing role of these systems 

in the health care structure of 

countries are also dealt with. 

Legislation and regulation of these 

systems and practitioners, an area 

of growing concern, the need for 

good preclinical toxicology studies 

and scientific clinical evaluation of 

the products and medicinal plants 

used for therapy are exhaustingly 

dealt with. The vital issue of protection 

of traditional systems of 

medicine and patenting of medicinal 

plants is discussed in detail. 

The book is replete with suggestions 

and ideas aimed at making 

traditional systems more effectively 

and more widely used for health 

care. The book also covers the prevailing 

situation regarding the use 

and other aspects of traditional 

medicine in the 10 Member countries 

of the South-East Asia Region 

of the World Health Organization. 

Edited by R.R. Chaudhury and Uton M. Rafei 

WHO Regional Office for South-East Asia 


South-East Asia Series, No. 39 

2002, vii + 309 pages [E] 

ISBN 92 9022 224 7 



Order no. 1560039 

Legal Status of 

Traditional Medicine and 

Complementary/Alternative 

Medicine 

A Worldwide Review 

Various types of traditional medicine 

and other medical practices referred 

to as complementary or alternative 

medicine are increasingly used in 

both developing and developed 

countries. In order to promote safe 

and appropriate use of these 

medicines and practices, as well as 

to ensure the quality of service and 

practitioners, national regulations are 

vital. Establishing national policies 

on traditional medicine, and/or 

complementary/alternative medicine 

and their medical practices, should 

therefore include creation of legal 

frameworks. 

This review summarizes the legal 

status of several major practices in 

traditional medicine and complementary/alternative 

medicine in 123 

coutries. It includes data on: the use 

of traditional and complementary/ 

alternative medicine; the regulatory 

situation of traditional and 

complementary/alternative remedies 

and practitioners; health insurance 

coverage of traditional and 

complementary/alternative 

medicine; education and training of 

practitioners of traditional and complementary/alternative 

medicine. 

<strong>Information</strong> provided in this review 

will be useful not only to policy 

makers,but also to researchers, 

universities, the public, insurance 

companies and pharmaceutical 

industries. 

2001, ix + 189 pages [E, R] 

ISBN 92 4 154548 8 



Order no. 1930190 

35


TRADITIONAL MEDICINE 

PSYCHOTROPIC DRUGS 











36 

WHO Traditional Medicine 

Strategy : 2002-2005 

WHO has developed this strategy 

for traditional medicine to enable 

this form of health care to better 

contribute to health security. 

It focuses on working with WHO 

Member States to define the role 

of traditional medicine in national 

health care strategies, supporting 

the development of clinical 

research into the safety and efficacy 

of traditional medicines, and 

advocating the rational use of 

tradtional medicine. 

2002, 61 pages 

WHO/EDM/TRM/2002.1 


http://www.who.int/medicines/library/tr 

m/trm_strat_eng.pdf 


Drug Dependence 

Thirty-third Report 

This report presents the 

recommendations of a WHO 

Expert Committee responsible 

for reviewing information on 

dependence-producing drugs to 

assess the need for their international 

control. The first part of the 

report contains a description 

of the procedure for the review of 

dependence-producing substances. 

This is followed by a critical review 

of five psychoactive substances 

(amfepramone, amineptine, 

buprenorphine, delta-9-tetrahydrocannabinol 

and tramadol). The 

report also discusses the substances 

that were pre-reviewed by the 

Committee, four of which (ketamine, 

zopiclone, butorphanol and 

khat) were recommended for 

critical review at a future meeting. 

The final section discusses the 

problems of the terminology used 

in reporting abuse-related adverse 

drug reactions and describes how 

confusion affects the reporting of 

adverse effects using the example 

of the selective serotonin reuptake 

inhibitors. 

Guidelines for the WHO 

Review of Dependenceproducing 

Psychoactive 

Substances for 

International Control 

2000, 22 pages [E, F] 




qsm/who-edm-qsm-2000-5/who-edmqsm-2000-5en.htm 

Narcotic and Psychotropic 

Drugs 

Achieving Balance in National 

Opioids Control Policy. 

Guidelines for Assessment 

The publication presents guidelines 

for governments to determine 

whether their national drug control 

policies have the legal and 

administrative framework to ensure 

medical availability of opioid 

analgesics, as recommended by 

the International Narcotics Control 

Board. 

2000, 37 pages [E, F] 



http://www.who.int/medicines/library/q 

sm/who-edm-qsm-2000-4/who-edmqsm-2000-4.htm 


2002 , 30 pages [E] 

ISBN 92 4 120915 1 



Order no.1100915


PERIODICALS AND SUBSCRIPTIONS 

The WHO Pharmaceuticals and Biologicals 

Subscription Package 

A yearly service offering automatic and immediate delivery of all 

WHO publications dealing with pharmaceuticals, pharmacy and 

biologicals. 

Introduced as a convenience for customers, the WHO 

Pharmaceuticals and Biologicals Subscription Package includes subscriptions 

to the following periodicals: WHO Drug <strong>Information</strong> 

and the Essential Drugs Monitor. The subscription also covers new 

reports of the WHO Expert Committees on biological standardization, 

specifications for pharmaceutical preparations, and drug 

dependence, plus all books relevant to drug research and 

development, manufacturing, prescribing, essential drugs, 

pharmacy, and international regulation and quality control. 

The WHO Pharmaceuticals and Biologicals Subscription Package 

2003 subscription rate: 

Sw.fr. 240–/US $192.00 

(includes handling charges and postage via surface mail) 

WHO Drug <strong>Information</strong> 

WHO Drug <strong>Information</strong> communicates pharmaceutical information 

that is either developed and issued by WHO or transmitted to WHO 

by research and regulatory agencies throughout the world. The journal 

also includes regular presentation of changes in the WHO Model 

List of Essential Drugs and newly proposed and recommended 

International Nonproprietary Names (INN) for Pharmaceutical 

Substances. 

Published quarterly in issues of approximately 50–60 pages each 

2003: Vol. 17 

ISSN 1010-9609 

Languages: available in English only 

2003 subscription rate: 

Sw.fr. 75.–/US $60.00 

(includes handling charges and postage via surface mail) 

37


PERIODICALS AND SUBSCRIPTIONS 

WEB ADDRESSES 




38 

WHO Pharmaceuticals 

Newsletter 

The aim of this Newsletter is to disseminate 

information on the safety 

and efficacy of pharmaceutical 

products, based on information 

received from our network of 

"drug information officers" and 

other sources such as specialized 

bulletins and journals, as well as 

partners in WHO. Also contains 

information on adverse drug 

reactions. 

2003, 4 volumes each year 

Contact: QSM@who.int 

Essential Drugs Monitor 

The Essential Drugs Monitor is produced 

and distributed by the WHO 

Department of Essential Drugs and 

Medicines Policy. It is published in 

Chinese, English, French, Spanish 

and Russian, and has a global readership 

of some 300,000 to whom 

it is free of charge. The Monitor 

carries news of developments in 

national drug policies, therapeutic 

guidelines, current pharmaceutical 

issues, educational strategies and 

operational research. 

2003, 2 issues per year 

Contact: The Editor, Essential Drugs 

Monitor, WHO, 1211 Geneva 27, 

Switzerland 

Email: medmail@who.int 

Essential Drugs in Brief 

The purpose of Essential drugs in 

brief is to share information on the 

latest country support provided or 

coordinated by the extended Drug 

Action Programme team (country, 

regional and HQ offices). It is an 

informal instrument aiming 

to share our experiences with 

colleagues within and outside 

WHO, who are active in the implementation 

of national drug policies 

at national and regional levels. 

2003, 3 issues per year 

Contact: dap@who.int 

Additional information and updates 

are available at the following 

WHO web sites: 

Medicines web site: 

http://www.who.int/medicines 

The public web site of the WHO/EDM 

Essential Drugs and Medicines Policy 

Department 

The Pharmaceutical <strong>Information</strong> and 

Documentation Centre web site: 


information/infdoccentre.shtml 

Email: edmdoccentre@who.int 

Mednet web site: 

http://mednet.who.int 

The Essential Drugs and Medicines 

extranet for focussed pharmaceutical 

information exchange 

The Essential Drug Monitor web site: 


information/infmonitor.shtml 

WHO Drug <strong>Information</strong> web site: 

http://www.who.int/druginformation


TITLE INDEX 

Adverse drug reaction terms: definition, 29 

Antimicrobial resistance in the Americas, 24 

Assessing new vaccines for national immunization 

programmes, 28 

Basic tests for drugs, 9 

Basic tests for pharmaceutical dosage forms, 9 

Basic tests for pharmaceutical substances, 9 

Benefit-risk balance for marketed drugs: evaluating 

safety signals, 29 

Biomedical research ethics: updating international 

guidelines, 28 

Cost-containment mechanisms for essential medicines, 

including antiretrovirals, in China, 6 

Counterfeit drugs, 16 

Drugs for the elderly, 24 

Eastern Mediterranean series 

No. 4: Guide to chemotherapy and chemoprophylaxis 

in bacterial infections, 23 

Effective drug regulation, 25 

Essential drugs in brief, 38 

European series 

No. 71: Drugs for the elderly, 24 

Globalization and access to drugs, 6 

Guide to chemotherapy and chemoprophylaxis 


Guide to drug financing mechanisms, 6 

Guide to good prescribing, 21 

Guidelines for ATC classification and DDD assignment, 14 

Guidelines for drug donations, 7 

Guidelines for preparing core clinical-safety 

information on drugs, 28 

Guidelines for safe disposal of unwanted 

pharmaceuticals in and after emergencies, 7 

Guidelines for the appropriate use of herbal medicines, 31 

Guidelines for the regulatory assessment 

of medicinal products for use in self-medication, 25 

Guidelines for the WHO review of dependence-producing 

psychoactive substances for international control, 36 

Guidelines on the use of international nonproprietary 

names (INNs) for pharmaceutical substances, 13 

Handbook on access to HIV/AIDS-related treatment, 3 

Health reform and drug financing, 6 

How to develop and implement a national drug policy, 5 

Implications of the DOHA declaration on the TRIPS 

agreement and public health, 6 

Importance of pharmacovigilance, 16 

Indicators for monitoring national drug policies, 5 

International nonproprietary names (INN) 

for pharmaceutical substances CD-ROM, 8 

International nonproprietary names (INN) for pharmaceutical 

substances: names of radicals and groups, 16 

International pharmacopoeia, 17-20 

International travel and health 2003, 25 

Legal status of traditional medicine 

and complementary/alternative medicine, 35 

Marketing authorization of pharmaceutical products with 

special reference to multisource (Generic) products, 26 

Medicinal plants in China, 32 

Medicinal plants in the Republic of Korea, 32 

Medicinal plants in the South Pacific, 33 

Medicinal plants in Viet Nam, 32 

Narcotic and psychotropic drugs, 36 

Network for monitoring the impact of globalization 

and TRIPS on access to medicines, 6 

New emergency health kit 1998, 4 

Operational principles for good pharmaceutical 

procurement, 7 

Pharmaceutical restrictions in use and availability, 16 

Practical guidelines on pharmaceutical procurement 

for countries with small procurement agencies, 7 

Publications from the South Centre, 27 

Public-private roles in the pharmaceutical sector, 6 

Quality assurance of pharmaceuticals, 10 

Quality control methods for medicinal plant materials, 10 

Regulatory situation of herbal medicines, 35 

Research guidelines for evaluating the safety 

and efficacy of herbal medicines, 31 

SEARO Regional Health Papers 

No.16: Essential drugs for primary health care, 4 

Safety monitoring of medicinal products, 16 

Safety of medicines, 16 

Selection and use of essential medicines, 3 

South-East Asia series 

No. 39: Traditional medicine in Asia, 35 

Teacher’s guide to good prescribing, 21 

Technical report series 

No. 889: WHO expert committee on biological 

standardization (48th report), 12 

No. 902: WHO expert committee on specifications 

for pharmaceutical preparations (36th report), 11 


standardization (50th report), 12 

No. 908: WHO expert committee on specifications 

for pharmaceutical preparations (37th report), 11 


standardization (51st report), 12 

No. 914: Selection and use of essential medicines, 3 

No. 915: WHO expert committee on drug 

dependence (33rd report), 36 

Traditional medicine in Asia, 35 

Use of common stems in the selection 

of international nonproprietary names (INN) 

for phamaceutical substances, 16 

Vitamin A supplements, 24 

Western Pacific series 

No. 3: Medicinal plants in China, 32 

No. 2: Medicinal plants in Viet Nam, 32 

No. 19: Medicinal plants in the South Pacific, 33 

No. 21: Medicinal plants in the Republic of Korea, 32 

No. 23: Guidelines for the appropriate use 

of herbal medicines, 31 

WHO basic training modules on GMP CD-ROM, 15 

WHO Collaborating centre for international 

drug monitoring, 30 

Cont. page 40 

39


TITLE INDEX 

WHO drug information, 37 

WHO expert committee on biological standardization, 12 

WHO expert committee on drug dependence, 36 

WHO expert committee on specifications 

for pharmaceutical preparations, 11 

WHO medicines bookshelf CD-ROM, 3 

WHO medicines strategy, 5 

WHO model formulary 2002, 2 

WHO model prescribing information: drugs used 



in parasitic diseases, 22 


in sexually transmitted diseases and HIV infection, 22 

WHO model prescribing information: drugs 

used in skin diseases, 23 

WHO monographs on selected medicinal plants, 33-34 

WHO pharmaceuticals and biologicals 

subscription package, 37 

WHO pharmaceuticals newsletter, 38 

WHO policy perspectives on medicines, 5 

WHO traditional medicine strategy, 36 

40


ADDRESSES 

World Health Organization, 

Geneva, Switzerland (Headquarters) 


CH - 1211 Geneva 27, Switzerland 

Tel. +41 22 791 21 11 

Telex 415416 OMS 

Fax +41 22 791 31 11 

Website: www.who.int 

Marketing & Dissemination 

Tel. +41 22 791 32 64/791 24 76 

Fax +41 22 791 48 57 

Email: publications@who.int 

Email for orders: bookorders@who.int 


Regional Offices of WHO 

Africa 

World Health Organization Regional Office for Africa 

P.O. Box 6 

Brazzaville, Congo 

Tel. +242 63 72 05/81 15 53/81 12 60 

Fax +242 81 19 39/81 14 09 

Email: afro@who.org 

Website: www.whoafr.org 

Americas 


Regional Office for the Americas 

Pan American Health Organization 

525, 23rd Street, N.W. 

Washington DC 20037, USA 

Tel. +1-202 861 3200 

Fax +1-202 223 5971 

Email: sales@paho.org 

Website: www.paho.org 

Eastern Mediterranean 

World Health Organization Regional Office for the 

Eastern Mediterranean 

WHO Post Office, Abdul Razzak Al Sanhouri Street 

(opposite Children's Library), Naser City 

Cairo 11371, Egypte 

Tel. +20 2 670 2535 

Fax +20 2 670 2492 

Email: dsa@emro.who.int 

Website: www.emro.who.int 

Europe 

World Health Organization Regional Office for Europe 

8, Scherfigsvej 

DK-2100 Copenhague Ø, Danemark 

Tel. +45 39 17 17 17 

Fax +45 39 17 18 18 

Email: publicationrequests@who.dk 

Website: www.euro.who.int 

South-East Asia 

World Health Organization Regional Office 

for South-East Asia 

World Health House, Indraprastha Estate 

Mahatma Gandhi Road 

New Delhi 110002, India 

Tel. +91 11 337 0804 to +91 11 337 8805 ext. 26-103 

Fax +91 11 337 0639 

Email: publications@whosea.org 

Website: www.whosea.org/rdoc 

Western Pacific 

World Health Organization Regional Office 


P.O. Box 2932 

Manila 1099, Philippines 

Tel. +63 2 528 80 01 

Fax +63 2 521 1036 ,536 0279, 536 0362 

Email: publications@wpro.who.int 

Website: www.wpro.who.int 

International Agency for Research 

on Cancer (IARC) 

International Agency for Research on Cancer 

150 cours Albert Thomas 

69372 Lyon Cedex 08, France 

Tel. +33 4 72 73 84 85 

Fax +33 4 72 73 85 75 

Email: press@iarc.fr 

Website: www.iarc.fr 

Council for International Organizations 

of Medical Sciences (CIOMS) 

C.I.O.M.S. 

c/o World Health Organization 

CH - 1211 Geneva 27, Switzerland 

Tel. +41 22 791 34 06 

Fax +4122 791 31 11 

Email: cioms@who.int 

Joint United Nations Programme 

on HIV/AIDS (UNAIDS) 

20 avenue Appia 

CH-1211 Geneva 27, Switzerland 

Tel. +41 22 791 46 51 

Fax +41 22 791 41 87 

Email: unaids@unaids.org 

Website: www.unaids.org 

41

oms-catalogue 15/07/03 11:36 Page 42


ORDER FORM 

World Health Organization Publications 

Order Form 

Prices shown are in Swiss francs and US dollars and are those charged by the World Health Organization (WHO), 

Marketing and Dissemination. They do not include local taxes and are subject to change without notice. Payment 

may be made in local currency to WHO sales agents, who will fix prices in accordance with current practices in the 

book trade. 

All orders should be addressed to the local sales agents listed in the catalogue, or to the bookseller which sent you 

this catalogue. For countries where no Agent has been appointed, or in case of difficulties, orders may be 

addressed to the World Health Organization, Marketing and Dissemination, CH-1211 Geneva 27, 

Switzerland, but must be paid for in US dollars, Swiss francs, EURO or UNESCO Coupons. 

Please send me the following titles in the quantity specified: 

Quantity Title Order no. Price 

Name 

Address 

Please add my name to your mailing list to receive a catalogue regularly. 

Postal Code City Country 

Tel.: Fax: Email: 

43 

Payment enclosed 

Please charge my credit card as follows* 

Visa American Express Eurocard/Acess/Mastercard 

My credit card number is: 

Expiry date: 

Signature: 

Credit card orders must be signed and the expiry date provided. 

*NB: Please check with your local WHO Sales Agent for acceptance of credit cards. 

Bank address: UBS SA, Agence de l’OMS, CH-1211 Geneva 27, Switzerland 

Swift Code UBSW CH ZH 12 A 

Swiss franc account no. 279-D3-100-897.0 

US dollar account no. 240-CO-169-920.3 

Euro account no. 240-CO-169-920.1 

Please return or fax this order to: 

WHO, Marketing & Dissemination 

CH-1211 Geneva 27 Switzerland 

Tel. +41 22 791 24 76 Fax +41 22 791 48 57 

Email address for direct orders: bookorders@who.int 


For customers in the USA, please return or fax this order to: 

WHO Publications Center USA 

49 Sheridan Avenue 

Albany NY 12210, USA 

Tel. +518 436-9686 Fax +518 436 7433 

Email: qcorp@compuserve.com 

MDI.PHA.203

oms-catalogue 15/07/03 11:36 Page 44


SALES AGENTS 

Sales Agents 

ARGENTINA: World Publications S.A. 

Av. Córdoba 1877, C1120 AAA Buenos 

Aires, Tel /Fax: (54 11) 4815 81 56, 

Email: ventaswp@wpbooks.com.ar 

AUSTRALIA: Hunter Publications, Tek 

Imaging, 58A Gipps Street, Collingwood, VIC 

3066, Tel: (61 3) 9417 53 61, 

Fax: (61 3) 9419 71 54, 

Email: admin@tekimaging.com.au 

BELGIUM: Patrimoine sprl, rue du Noyer 

168, 1030 Bruxelles, 

Tel/Fax: (32 2) 736 68 47 

Email: Patrimoine@chello.be. 

CANADA: Canadian Public Health 

Association, 1565 Carling Avenue, 

Suite 400, Ottawa, Ont. K1Z 8R1, 

Tél : (1 613) 725 37 69, Fax: (1 613) 725 98 

26, Email: hrc/cds@cpha.ca; 

Renouf Publishing Co. Ltd, 

1-5369 Canotek Road, Ottawa, Ont. K1J 9J3, 

Tel: (1 613) 745 2665, Fax: (1 613) 745 

7660, Email: order.dept@renoufbooks.com 

CAMEROON: Buma Kor & Co. Ltd, B.P. 727, 

40 rue Nachtigal (Montée Cinéma 

Abbia),Yaounde, Tel/Fax: (237) 23 07 68, 

Email: b.kor@iccnet.cm 

CHILE: Miguel Concha S.A., Alferez Real, 

1414 Providencia, Casilla 7 Correo 22, 

Santiago de Chile, Tel: (56 2) 655 15 45, 

Fax: (56 2) 274 66 55, 

Email: miguelconcha@entelchile.net 

DENMARK: Swets Blackwell AS, P.O. Box 

173, 1005 Copenhagen Q, 

Tel: (45) 39 15 79 15, Fax: (45) 39 15 79 10 

Email: info@dk.swetsblackwell.com 

EGYPT: MERIC, 2 Bahgat Aly Street, Cairo, 

Tel: (202) 341 38 24; Fax: (202) 341 93 55, 

Email:inquiry@meric-co.com; The Middle East 

Observer, 41 Sherif Street, Cairo, 

Tel:392 6919, Fax 393 97 32, 

Email: inquiry@meobserver.com 

FINLAND: Stockmann Akateeminen 

Kirjakauppa, P.O. Box 23, 00381 Helsinki, 

Tel: (358)9 121 44 03, Fax: (358) 9 121 44 

50, Email: akajournals@stockmann.fi 

FRANCE: Librairie Privat-Arnette, 2 rue 

Casimir Delavigne, 75006 Paris, Tél: (33 1) 

5542 87 87, Fax: (33 1) 55 42 87 88, 

Email : arnette@privat.fr; Librairie Lavoisier, 

Technique et Documentation, 14 rue de 

Provigny, 94236 Cachan Cedex, Tél: (33 1) 

47 40 67 00, Fax: (33 1) 47 40 67 02, Email: 

edition@Lavoisier.fr; E.M. Inter, Allée de la 

Croix-Bossée, 94234 Cachan Cedex, Tel: (33 

1) 45 46 15 00, Fax: (33 1) 47 40 67 99, 

Email: bal@eminter.fr; Librairie Luginbuhl, 36 

boulevard de Latour-Maubourg, 75007 Paris 

Tél : (33 1) 45 51 42 58, Fax: (33 1) 45 56 07 

80 Mél. : liblug@club-internet.fr; Sauramps 

Médical, 11 Bd Henri IV, 34000 Montpellier, 

Tél : (33 04 67) 41 39 70, 

Fax: (33 04 67) 52 59 05, 

Email: sauramps.medical@livresmedicaux.com 

GERMANY: UNO -Verlag GmbH, Am 

Hofgarten 10, 53113 Bonn, Tel: (49 228) 94 

90 20, Fax: (49 228) 94 90 222, 

Email: bestellung@uno-verlag.de; 

Govi-Verlag GmbH, Ginnheimerstrasse 26, 

Postfach 5360, 65728 Eschborn, Tel: (49 

6196) 928 251, Fax: (49 6196) 928 259. 

Buchhandlung Alexander Horn, 

Friedrichstrasse 34, 65185 Wiesbaden, 

Tel: (49 611) 99235 40/41, Fax: (49 611) 

99235 43, Email: alexhorn1@aol.com 

GREECE: G.C. Eleftheroudakis S.A., 

Librairie internationale, 17 Panepistimiou, 

105-64 Athens, Tel: (30 1) 331 41 80 , 

Fax: (30 1) 323 98 21 

INDIA: WHO Regional Office for South- 

East Asia, World Health House, 

Indraprastha Estate, Mahatma Gandhi 

Road, New Delhi 110002 ,Tel: (91 11) 

331 7804, Fax: (91 11) 331 8607, 

Email: Publications@whosea.org 

ISRAEL: Yozmot Ltd, P.O. Box 56055, Tel 

Aviv 61560, Tel: (972) 3 528 48 51, Fax: 

(972) 3 528 53 97, Email: books@yozmot.com 

ITALY: Edizioni Minerva Medica, Corso 

Bramante 83-85, 10126 Turin 

Tel: (39 011) 67 8282, Fax: (39 011) 67 

45 02, Email: journals.dept@minervamedica.it 

JAPAN: Maruzen Co. Ltd., P.O. Box 

5050, Tokyo International, 100-31, 

Tel: (81 3) 3272 7211, Fax: (81 3) 3274 

3238, Email: K_iwata@maruzen.co.jp 

JORDAN: Jordan Book Centre Co. Ltd, 

P.O. Box 301 Al-Jubeiha, Amman 

11941,Tel: 5151 882, Fax: 5152 016, 

E.mail: jbc@go.com.jo 

Global Development Forum, PO Box 

941488, Amman 11194, 

Tel: 6465 61 24, Fax: 6465 61 23, 

Email: gdf@index.com.jo 

KENYA: Text Book Center Ltd, P:O. Box 

47540, Nairobi, Tel: (254) 233 03 42, 

Fax: (254) 233 81 10 

MEXICO: Librería Internacional de C.V., 

Av. Sonora 206, 06100-Mexico, D.F., 

Tel: (52 5) 265 11 65, Fax: (52 5) 265 11 

64, Email: libinter@compuserve.com.mx 

NETHERLANDS: De Lindeboom 

Internationale Publicaties b.v., P.O. Box 

202, NL-7480 AE Haaksbergen, 

Tel: (31) 53 574 00 04, Fax: (31) 53 572 

92 96, Email: books@delindeboom.com 

NEW ZEALAND: Medical Books (New 

Zealand), Ltd, 8 Park Avenue, P.O. Box 

8565, Symonds Street, Auckland 3, 

Tel: (64 9) 373 3773, Fax: (64 9) 373 

3282 

NIGERIA: Mr G. Obiaga, 28 Onitsha 

Road, P.O. Box 370, Nnewi, Anambra 

State, Tel/Fax:(234) 46 460 273 

NORWAY: Academic Book Center, PO 

Box 2728, St Hanshaugen, 0131 Oslo, 

Tel: (47 22) 99 48 40, Fax: (47 22) 20 89 

71, Email: abc@fribokhandel.no 

PERU: Euroamerican Bussiness SA, Ca. 

las Begonias No. 183, Dept. 202, Urb. 

J.C. Mariategui, Lima 35,Tel: (51 1) 

725 9152, Fax: (51 1) 283 0129, 

Email: euroamerican@terra.com.pe 

POLAND: Ars Polona, ul. Krakowskie 

Przedmiescie 7, 00-950 Warszawa, 

Tel: (48 ) 22 826 12 01, Fax: (48) 22 826 47 

63, Email: books119@arspolona.com.pl 

PORTUGAL: Livraria Rodrigues, 188 Rua da 

Ouro, 1100 Lisboa, 

Tel: (351 21) 342 48 57, 

Fax: (351 21) 343 13 02 ; Prata & Rodrigues 

Publicaçoes, Ltda, Estrada da Luz, 90-11º H, 

1600-160 Lisboa,Tel: (351 21) 722 35 28/29, 

Fax: (351 21) 722 35 31, Email: 

ip263692@ip.pt; LUSODOC, Documentação 

Técnico-Cientifica Ltda, Rua Cruzado 

Osberno 3,5°, Dt°, 1900 Lisboa, 

Tel: (351) 21 815 3312, Fax: (351) 21 813 

0641, Email: postmaster@lusodoc.pt 

SINGAPORE: Select Books, 19 Tanglin Road, 

03-15 Tanglin Shopping Center, Singapore 

247909, Tel: (65) 732 15 15, Fax: (65) 736 

08 55, Email:info@selectbooks.com.sg 

SOUTH AFRICA: Democratic Nursing 

Organisation of South Africa (DENOSA), P.O. 

Box 1280, 605 Church street, Pretoria (T) 

0001, Tel: (27 12) 343 2315, Fax: (27 12) 

344 0750; Email: info@denosa.org.za 

SPAIN: Librería Díaz de Santos, Lagasca, 95, 

P.O. Box 6050, 28006 Madrid, Tel: (34 91) 

781 94 80, Fax: (34 91) 575 55 63; 

Email:librerias@diazdesantos.es 

SWEDEN: Akademibokhandeln, Mäster 

Samuelsgatan 28, Box 7634, 103 94 

Stockholm,Tel: 0046-8-613 61 30, 

Fax: 0046-8-24 25 43, 

Email: marikka.lindahl@city.akademi-bokhandeln.se; 

PRIO Info Center AB, 

Prastgardgatan 1-3, 172 29 Sundbyberg, 

Tel: (46) 8 441 17 40, Fax: (46) 8 652 81 15, 

E.mail: info@prioinfo.se 

SWITZERLAND: Huber & Lang, Hans Huber 

AG, Länggassstrasse 76, 3000 Bern 9, 

Tél: (41 31) 300 45 00, Fax : (41 31) 300 45 

90, Email: WHO@HansHuber.com 

TRINIDAD & TOBAGO: Systematics Studies 

Ltd, St Augustine Shopping Centre, Eastern 

Main Road, St Augustine, Tel: (1 809) 645 

8466, Fax:(1 809) 6458467, 

Email:tobe@trinidad.net 

UGANDA: Gustro Ltd, PO Box 9997, 

Kampala , Tel: (256) 41 251 467, 

Fax: (256) 41 251 468 

Email: Gustro@swiftuganda.com 

UNITED KINGDOM: The Stationery Office 

Publications Centre, 51 Nine Elms Lane, 

London SW8 5DR, Tel: (44) 0870 660 5522. 

Fax: (44) 0870 600 5533. 

Email: ipa.enquiries@theso.co.uk 

UNITED STATES OF AMERICA: (Books) 

WHO Publications Center USA, 49 Sheridan 

Ave., Albany, NY 12210, Tel: (1-518) 436 

9686, Fax: (1-518) 436 74 33, 

Email: Qcorp@compuserve.com. 

Other countries please contact: 

Autres pays, veuillez prendre contact avec: 

WHO, Marketing & Dissemination, 

CH-1211 Geneva 27, Switzerland 

Tel: +41 22 791 24 76 

Fax: +41 22 791 48 57 

Email: bookorders@who.int 

45



Marketing and Dissemination 

Address: 

CH-1211 Geneva 27 

Switzerland 

Telephone: 

+41 22 791 24 76 

Fax: 

+41 22 791 48 57 

Email: 

publications@who.int 

Email for orders: 

bookorders@who.int 

Order online: 

http://bookorders.who.int 


Internet address: 

www.who.int 

WHO Model Formulary 2002 

MDI.PHA.203

Information Products on Pharmaceuticals - Renouf Publishing Co. Ltd.

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?